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1. Introduction 
 
1.1 Breast cancer 
 
Breast cancer is the most common female cancer in the world and the leading cause of 
cancer death among females both in economically developed and developing countries, 
resulting in nearly 1.4 million new cases (23% of the total new cancer cases) and 
approximately 460,000 cancer deaths (14% of all cancer deaths) in 2008. Although breast 
cancer death rates have been decreasing in the last two decades mainly because of major 
advances in understanding, diagnosing and treating this disease, several unresolved 
problems remain (Jemal, 2011). Even in highly developed countries such as the United 
States, breast cancer is the second most common malignancy among females as well as the 
second leading cause of cancer death in females with about 230,500 new cases and 39,500 
breast cancer deaths expected for 2011 (DeSantis et al., 2011). 
Female gender, age, family history and genetic mutations in the breast cancer 1 (BRCA1) or 
BRCA2 genes are the strongest risk factors for breast cancer. Further risk factors include 
early menarche or late menopause, nulliparous, oral contraceptives and hormone 
replacement therapy, increased breast density, lack of physical activity as well as alcohol 
consumption (Hulka and Moorman, 2008). 
Unfortunately there are no early symptoms in breast cancer. Breast lumps as localized, 
palpable indurations or swellings of the breast are usually the first noticeable sign of an 
already advanced carcinoma. In economically developed countries most breast carcinomas 
are diagnosed as a result of an abnormal mammogram without any clinical symptoms at 
that time. Nevertheless, in patients with locally advanced breast cancer and inflammatory 
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breast cancer characteristic clinical signs can be observed (Giordano, 2003; Singletary and 
Cristofanilli, 2008).  
Today most breast carcinomas are diagnosed as a result of abnormal mammography. When 
a suspect correlate is found in the mammogram further breast imaging characterization 
such as spot compression views and ultrasonography is performed to decide the need for 
breast biopsy. All primary breast tumors have to be assayed for estrogen (ER) and 
progesterone (PR) hormone receptors since hormone receptor-positive tumors have been 
shown to benefit from endocrine treatments with ER-antagonists such as tamoxifen or 
aromatase inhibitors. Furthermore it is being suggested that all primary breast cancers be 
assayed for the expression of human epidermal growth factor receptor 2 (HER2). Around 
20% of breast cancer patients show HER2 overexpression and can benefit from treatment 
with trastuzumab, a monoclonal antibody that interferes with HER2 (Hayes, 2011). 
In general the treatment of breast cancer is highly complex. With the goal being a tailored 
approach, the selection of a therapeutic strategy depends on clinical factors, TNM 
classification, morphological diagnosis, immunohistochemical assessment and recently also 
on molecular typing. In early stage breast cancer, treatment of the locoregional disease 
includes breast conserving surgical therapy (BCT) together with radiation therapy. 
Additionally, an adjuvant or neoadjuvant systemic therapy needs to be performed. 
Depending on the precise breast cancer classification, therapy is performed with endocrine 
drugs, one or a combination of chemotherapeutic agents and/or biological drugs (Hayes, 
2011). 
While major advances have been achieved in the treatment of early breast cancer, the 
management of metastatic breast cancer remains extremely challenging even with the 
availability of new and more efficient drugs, which have to some extent improved the 
patients’ median survival (Gennari et al., 2005; Chia et al., 2007). Still, the majority of 
women with metastatic breast cancer will die of the disease. 
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In the last years major contributions have been made towards a better understanding of 
cancer biology. Nonetheless, the exact origin and etiology of breast cancer remains to be 
elucidated. It is now known that breast cancer is a heterogeneous disease with different 
tumor subclasses defined by gene expression patterns. The use of DNA microarray analysis, 
apart from morphological and immunohistochemical assessment, revealed a 
heterogeneous gene expression profiling of breast cancer. Elaborated studies have shown 
that there are five molecular tumor subclasses with different clinical outcomes including 
normal breast-like, basel-like, luminal A, luminal B and HER2+/ER- breast cancer with the 
main subtypes being the luminal A and the basel-like type (Perou et al., 2000; Sorlie et al., 
2001; Sorlie et al., 2006). The tumor subtype-specific events as well as the cell of origin of 
these subtypes are being intensely studied and remain controversial (Visvader, 2011). 
Breast cancer progression from atypical hyperplasia via ductal carcinoma in situ and 
invasive ductal carcinoma to subsequent metastatic disease is tremendously complex and 
poorly understood. Some studies have addressed the question of cancer progression by 
analyzing differences in geno-phenotypic patterns of breast carcinomas at different stages 
and propose a branching molecular evolutionary model for the development and 
progression of breast cancer (Shackney and Silverman, 2003). Yet this hypothetical cancer 
model, which is focused mainly on genetic profiling of epithelial cancer cells and does not 
take into account the potential role of the surrounding tumor microenvironment, cannot 
sufficiently explain breast cancer progression. 
Our understanding of breast cancer progression and metastasis lags far behind and only a 
perception of breast cancer as whole entity consisting of “the cancer cell” as well as its 
microenvironment will allow scientists to understand the cancer continuum from initiation 
to metastasis and to eventually develop more efficient strategies in the battle against this 
fatal disease. 
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1.2 The tumor-stroma microenvironment 
 
In the late 19th century Stephen Paget was the first scientist to hypothesize that both the 
cancer cell and its microenvironment are important for the spreading of cancer. Paget 
studied over 700 autopsy records of fatal breast cancer and noted that metastases were 
not randomly distributed in the body. Instead they were found more often in certain 
organs, suggesting that those organs provided better conditions for secondary cancer 
growth. Hence he hypothesized that even if “The best work in the pathology of cancer is 
now done by those who are studying the nature of the seed *…+” (i.e. the cancer cell), the 
“*…+ observation of the properties of the soil" (i.e. the surrounding) "may also be useful.” 
(Paget, 1889).  
Ever since, researchers are studying the so-called “seed and soil” theory of cancer, trying to 
understand the molecular interactions of a tumor with its stroma. Especially in the last 
years it has become apparent that while tumor epithelial cells with their transforming 
genetic and epigenetic events are essential for the initiation of breast cancer and other 
cancers, a variety of cells of the surrounding microenvironment actively influence tumor 
progression and its hallmarks - proliferation, migration and invasion (Liotta and Kohn, 2001; 
Allinen et al., 2004).  
In breast cancer and other cancers the stromal microenvironment, also referred to as 
“reactive stroma”, is defined as the extracellular matrix (ECM) together with the non-
malignant cells surrounding the tumor. Although the cells that populate the stroma are not 
neoplastic, they seem to influence tumor cell behavior. These cells range from vascular cells 
(e.g. pericytes and endothelial cells), immune and inflammatory cells (e.g. lymphocytes, 
macrophages and monocytes) to reactive stromal fibroblasts (Liotta and Kohn, 2001). The 
neoplastic epithelial cancer cells and those of the microenvironment are in constant 
“conversations” and there is active recruitment of stromal cells into the tumor. The stroma 
cells produce additional tumor growth factors, cytokines, chemokines and matrix 
Introduction 
 
8 
metalloproteinases that essentially contribute to tumor progression. These stromal cells 
and the substances they produce do not only offer a promising target for new anti-cancer 
drugs, but could also serve as a source for novel biomarkers apart from those currently 
used, which are mostly expressed by the cancer cells themselves (Sund and Kalluri, 2009). 
 
1.3 Carcinoma-associated fibroblasts within 
tumor stroma 
 
From the variety of cells populating the stromal microenvironment the importance of 
reactive stromal fibroblasts (also called carcinoma-associated (myo)fibroblasts [CAFs]) in 
supporting tumor progression has been pointed out intensively in the past years (Kunz-
Schughart and Knuechel, 2002; Kalluri and Zeisberg, 2006; Angeli et al., 2009). Although 
carcinoma-associated fibroblasts are a heterogeneous cell population, they consist mainly 
of myofibroblasts, which is why CAFs are often referred to as tumor-activated 
myofibroblasts. These cells differ from normal fibroblasts not only by their phenotype but 
also due to their production of various growth factors, chemokines, cytokines and proteins 
of the ECM, all known to possess tumor-promoting functions (Orimo and Weinberg, 2007; 
Ostman and Augsten, 2009). 
Myofibroblasts have originally been described in skin wounds where they contract the 
stroma, bringing the epithelial borders closer together and thereby facilitate wound healing 
(Grinnell, 1994). However, apart from their importance in wound healing, myofibroblasts 
also play a crucial role in carcinomas, which Harold Dvorak referred to as “wounds that 
never heal” (Dvorak, 1986). Indeed wound healing and carcinomas seem to have quite 
remarkable molecular similarities since both, the process of wound healing as well as the 
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development and progression of cancer, rely on constant interactions between epithelial 
cells and the surrounding stroma (Schafer and Werner, 2008). 
Tumor-activated myofibroblasts/CAFs are characterized as large, spindle-shaped cells 
defined by stress fibers, well developed cell-matrix-interactions and the expression of 
different immunohistochemical markers, most importantly alpha smooth muscle actin (α-
SMA), which is used as the main detecting marker in most studies on the subject of CAFs. α-
SMA, initially described in cells of smooth muscle lineage, is one of six different actin 
isoforms in mammalians. It is a major constituent of actin filaments forming the 
cytoskeleton which enables cell-contraction and locomotion (RonnovJessen and Petersen, 
1996). It is known that α-SMA expressing myofibroblasts are abundant in most invasive 
human breast cancers (Sappino et al., 1988) and other epithelial carcinomas such as that of 
the prostate, colon, lung and uterus where they form reactive stroma (Orimo et al., 2001). 
Moreover, translational studies of the tumor stroma in different carcinomas including 
breast and colorectal cancer have demonstrated that α-SMA positive CAFs can reflect 
disease outcome or recurrence (Tsujino et al., 2007; Yazhou et al., 2004). 
Orimo and his group studied the functional contributions of these altered fibroblasts in 
breast carcinoma. They found that CAFs present in invasive human breast cancer stimulate 
tumor growth and recruit circulating endothelial progenitor cells (EPCs) into the tumor 
furthering neoangiogenesis through secretion of stromal cell-derived factor 1 (Orimo et al., 
2005) that binds to the C-X-C chemokine receptor 4 (CXCR4) expressed on cancer cells 
(Muller et al., 2001). Physiologically, the homeostatic chemokine stromal cell-derived factor 
1 (SDF-1) mainly regulates hematopoietic cell trafficking and lymphoid tissue architecture. 
However within multiple malignancies the SDF-1/CXCR4 axis can be deregulated, leading to 
the promotion of cancer cell migration and metastasis (Teicher and Fricker, 2010). 
Moreover, CAFs affect the invasive potential of cancer cells by providing multiple 
proinvasive factors through direct cell-cell contacts as well as paracrine signaling (De et al., 
2008). 
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One important invasive-growth promoting factor specifically present in tumor-activated 
myofibroblasts is the hexameric extracellular matrix glycoprotein tenascin-C, one of four 
members of the ECM family of tenascins, and a well established cell marker for CAFs apart 
from α-SMA. Tenascins are typically expressed at sites of tissue remodeling as seen during 
wound repair and neovascularization or in pathological states such as inflammation or 
tumorigenesis and modulate the cell adhesion and migration (Hsia and Schwarzbauer, 
2005). Tenascin-C produced by myofibroblasts in vitro has been shown to facilitate tumor 
cell invasion in human colon cancer (De et al., 2004) and a recently performed mouse study 
by O´Connell et al. proved that tenascin-C plays a crucial role in the metastatic colonization 
of murine breast cancer cells in vivo (O'Connell et al., 2011). Additionally, high expression 
levels of tenascin-C in patients with breast cancer have been reported to correlate with 
poor disease outcome (Suwiwat et al., 2004). 
A further important proinvasive factor provided by the tumor stroma is the chemokine C-C 
motif ligand 5 (CCL5). Current studies indicate that this inflammatory chemokine is being 
secreted by tumor-associated fibroblasts in reactive stroma of breast cancer as well as by 
bone marrow derived stem cells (BMSCs) when admixed with breast cancer cells and 
promotes tumor-enhancing activities (Karnoub et al., 2007; Mishra et al., 2011). It was 
shown that human adipose tissue derived stem cells interacting with breast cancer cells can 
be a source of CCL5 which enhances cancer cell invasion in vitro  (Pinilla et al., 2009). 
Furthermore CCL5 together with CCL2 support the migration of blood-derived monocytes 
into the tumor which consequently differentiate into tumor-activated macrophages and 
release a large variety of promalignant factors, again enhancing tumor progression (Mishra 
et al., 2011). 
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1.4 The origin of carcinoma-associated 
myofibroblasts 
 
The molecular origin of CAFs and the mechanism by which CAFs develop into tumor 
promoting cells is not conclusively established and remains a subject of controversy (Haviv 
et al., 2009). It is likely that the origin of myofibroblasts within the desmoplastic stroma is 
determined by the type of carcinoma and that various cellular lineages can contribute to 
the overall count of CAFs, again depending on the type of cancer. 
It has often been suggested that CAFs could originate from host fibroblasts (Haviv et al., 
2009). One recent study dealing with the origin of these cells found that CAFs present in 
liver metastases from colorectal cancer displayed a phenotype similar to that of the host 
portal-located liver fibroblasts (Mueller et al., 2007).  
Other studies have suggested epithelial to mesenchymal transition (EMT) as well as 
endothelial to mesenchymal transition (EndMT) as a source of carcinoma-associated 
fibroblasts. As for EMT it has been argued that both epithelial cancer cells and normal 
epithelial cells adjacent to malignant cells could contribute to the pool of tumor-activated 
fibroblasts (Kalluri and Zeisberg, 2006; Radisky et al., 2007). Zeisberg et al. showed that 
TGFβ1 induced primary mouse endothelial cells to converse into fibroblast-like cells in vitro. 
This transition could also be observed in two different mouse models in vivo where EndMT 
significantly contributed to the total cell population of CAFs (Zeisberg et al., 2007). 
Recent studies have shown that at least a subset of myofibroblasts in cancer originate from 
circulating bone marrow derived stem cells that infiltrate the tumor stroma (Direkze et al., 
2004; Ishii et al., 2003; Mishra et al., 2008). Mishra et al. found that in breast cancer these 
BMSC-derived myofibroblasts did also exhibit functional properties of reactive stroma 
including the ability to stimulate tumor cell growth both in vitro and in vivo as 
demonstrated by a co-implantation model where cancer cells were admixed with BMSCs 
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(Mishra et al., 2008). In another in vivo study about inflammation-induced gastric cancer, 
approximately 20% of the carcinoma-associated myofibroblasts were derived from BMSCs 
(Quante et al., 2011). In a further study the human pancreatic cancer cell line Capan-1 was 
subcutaneously xenotransplanted into immunodeficient mice and the stromal formation 
was analyzed after 28 days revealing that approximately 40% of all CAFs originated from 
BMSCs (Ishii et al., 2003). 
Jeon and his group showed that in ovarian cancer lysophosphatidic acid (LPA) present in 
patients´ ascites can stimulate the differentiation of adipose tissue derived mesenchymal 
stem cells towards carcinoma-associated myofibroblasts (Jeon et al., 2008). However, the 
involvement of tissue resident mesenchymal stem cells from the adipose tissue in breast 
cancer stroma formation has not been investigated so far. Recent studies from our and 
other groups indicate that adipose tissue contains multipotent stem cells. These cells 
express specific mesenchymal stem cell surface markers such as cluster of differentiation 29 
(CD29), CD44, CD90, CD105 (Bai et al., 2007a; Bai et al., 2007b) and are capable of multi-
lineage differentiation (Direkze et al., 2004; Gimble et al., 2007; Zuk et al., 2001). The multi-
lineage differentiation potential of these cells into adipogenic, osteogenic, neurogenic and 
hepatogenic lineage has also been demonstrated in our laboratory (Bai et al., 2007b). 
Since adipose-tissue derived stem cells (hASCs) are locally adjacent to the breast tissue and 
the female breast is composed of a vast quantity of adipose tissue, we hypothesized that a 
considerable amount of tumor-associated myofibroblasts in breast cancer could arise from 
hASCs. Hence we sought to elucidate whether α-SMA-positive CAF-like cells can indeed 
originate from hASCs within the breast cancer microenvironment and if so, which molecular 
mechanisms are involved in the process of differentiation. 
Since it is known that TGFβ can promote the differentiation of mesenchymal precursors 
into fibroblasts and/or myofibroblasts (Derynck and Akhurst, 2007) we focused on the role 
of TGFβ within the potential differentiation of hASCs towards α-SMA positive CAFs in breast 
carcinoma. 
Introduction 
 
13 
In cancer the cytokine TGFβ can be both suppressing and promoting cancer growth which is 
why it is also known as the molecular “Jekyll and Hyde” of cancer (Bierie and Moses, 2006). 
Human TGFβ belongs to a superfamily comprising more than 30 different members of 
which most exist in variant forms (e.g. TGFβ1, 2 and 3). The TGFβ receptor is a dimer 
composed of two pairs of receptors (serine/threonine kinases) known as the type I and type 
II receptors (TGFβ RI/II). The type II receptor phosphorylates the TGFβ I receptor upon 
binding TGFβ, which in turn transmits the signal by phosphorylating and activating Smad2 
and Smad3 transcription factors. Within the cell nucleus Smad2 and Smad3 form a complex 
with Smad4 which binds to the DNA and can activate or suppress target genes (Shi and 
Massague, 2003; Massague, 2008). 
The systemic and particular activities of TGFβ are highly complex and context specific. TGFβ 
can affect most physiological processes and specific actions on certain cells depend on the 
specific circumstances of these cells´ environment. In normal cells TGFβ modulates cell 
differentiation, cytostasis and apoptosis and can suppress inflammation and stroma-
derived mitogens. In breast cancer however, malignant progression leads to loss of tumor-
suppressive responses in cancer cells. The cancer cells can now exploit TGFβ to their 
advantage in order to initiate the production of tumor-supporting factors (e.g. cytokines, 
proteases), for evasion of immune surveillance, invasiveness and metastatic dissemination, 
and for the recruitment of other cells such as myofibroblasts into the tumor 
microenvironment (Massague, 2008). TGFβ is implicated in breast cancer progression and 
clinical studies in human primary breast cancer demonstrated that high protein levels of 
TGFβ1 were correlated with a shorter disease-free survival (Desruisseau et al., 2006; Sheen-
Chen et al., 2001). 
The origin of TGFβ in cancer depends on the cancer-type and can range from the cancer 
cells themselves to various cells of the microenvironment, with each source having its own 
functional effects (Massague, 2008). 
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1.5 Aim of the study 
 
It has been widely recognized that carcinoma-associated myofibroblasts, frequently present 
in desmoplastic breast cancer stroma, play a crucial role in supporting tumor progression. 
Nonetheless, the cell type of origin and the molecular mechanisms by which these cells 
develop into tumor-promoting mediators has not been conclusively established and 
remains debated. Different types of cells have recently been proposed to be precursors of 
myofibroblasts in breast cancer. However the involvement of human adipose tissue derived 
stem cells (hASCs) in this context had not been investigated so far. The aim of this study 
was to investigate whether carcinoma-associated myofibroblasts can originate from hASCs, 
which are locally adjacent to epithelial breast cancer cells and might therefore represent 
early response cells within breast cancer. 
 
The goal of this project was therefore to answers the following questions in the given order: 
1. Can hASCs differentiate into myofibroblast-like cells when interacting with human 
breast cancer cells in vitro? 
2. Is TGFβ1 involved in this differentiation? 
3. Do myofibroblast-like cells generated from hASCs exhibit functional properties of 
carcinoma-associated myofibroblasts? 
In particular: 
a. Do these altered cells produce the tumor-promoting chemokines SDF-1α and 
CCL5? 
b. Do these altered cells influence the invasive potential of breast cancer cells in 
vitro? 
Materials and methods 
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2. Materials and methods 
 
2.1 Materials 
 
2.1.1 Apparatuses 
Camera Cool SnapEZ    Photometrics 
Centrifuge and micro-centrifuge  Beckmann 
Centrifuge, Model 5682   Forma Scientific 
Digital camera     Canon 
FACSAria II cell sorter    BD Biosciences 
FACSCalibur cell sorter    BD Biosciences 
Heating block     Fisher Scientific 
Hemacytometer    Hausser Scientific 
Incubator, Steri-Cult 200   Forma Scientific 
Laminar Flow Hood    NuAire 
Microscope Axiovert 25   Carl Zeiss 
Microscope Axiovert S100   Carl Zeiss 
RotoShaker     Scientific Industries 
Spectrophometer µQuant   BioTek Instruments 
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2.1.2 Cells 
Human ASCs  Established from subcutaneous tissue of 
patients undergoing elective liposuction 
MCF7 cancer cells    American Type Culture Collection 
MDAMB231 cancer cells   American Type Culture Collection 
GFP-labeled MDAMB231  American Type Culture Collection cells 
transfected with pLOX/EW-EGFP lentivirus 
 
2.1.3 Tissue culture materials 
Centrifuge tubes; 15ml, 50ml    Greiner Bio One 
Fetal bovine serum     Atlanta Biologicals 
HBSS       Cellegro 
L-glutamine      Cellegro 
Liberase Blendzyme 3     F. Hoffman-La Roche Ltd 
PBS       Cellegro 
Penicillin solution     Cellegro 
Polystyrene round bottom tubes   Becton Dickinson Labware 
Steriflip filter; 0.45µm, 100µm    Millipore 
Streptomyicin solution     Cellegro 
Tissue culture flasks; T25, T75, T175   Greiner Bio One 
Tissue culture plate; 24 well    Becton Dickinson Labware 
Tissue culture plate; 6 well    Greiner Bio One 
Trypsin- EDTA      Sigma-Aldrich 
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2.1.4 Antibodies 
Alexa Fluor 488-conjugated goat anti-mouse AB Invitrogen, Molecular Probes 
Alexa Fluor 488-conjugated goat anti-rat AB  R&D Systems 
Anti-phospho-Smad2; catalog # 3101   Cell Signaling 
Anti-phospho-Smad3; clone EP823Y   Epitomics 
Anti-Smad2; catalog # 3122    Cell Signaling 
Anti-Smad3; clone EP568Y    Epitomics 
Anti-tenascin-C; clone 578    R&D Systems 
Anti-tenascin-C; clone BC-24    Sigma-Aldrich 
Anti-TGFβ RII; clone H-567    Santa Cruz Biotechnology 
Anti-TGFβ1      R&D Systems 
Anti-α-SMA; clone 1A4     Sigma-Aldrich 
Anti-α-SMA; clone E184    Abcam 
Anti-β-Actin; clone AC15    Sigma-Aldrich 
Fluorescein-conjugated anti-TGFβ RII   Santa Cruz Biotechnology 
Normal chicken IgY     R&D Systems 
Normal mouse IgG isotype-matched controls  eBioscience 
Normal rat IgG isotype-matched controls  eBioscience 
PE-conjugated anti-human CD105   eBioscience 
PE-conjugated anti-human CD14   eBioscience 
PE-conjugated anti-human CD29   eBioscience 
PE-conjugated anti-human CD34   eBioscience 
PE-conjugated anti-human CD90   eBioscience 
PerCP-conjugated anti-human CD44   eBioscience 
PerCP-conjugated anti-human CD44   eBioscience 
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2.1.5 Western blot materials 
BioMaxTM MR single-emulsion film; 5x7 inch  Sigma-Aldrich 
Biotinylated protein ladder    Cell Signaling 
Blotting device, semi-dry    BioRad 
Cell lysis buffer      Cell Signaling 
ECLTM detection reagents    GE Healthcare 
Mini-Protean® Tetra Cell System   BioRad 
Polyvinylindene difluoride membranes   Millipore 
Protease inhibitor cocktail    Roche Diagnostics 
Running buffer      BioRad 
SDS Page gels      BioRad 
 
2.1.6 Assays and kits 
Human CCL5 Quantakine kit    R&D Systems 
Human SDF-1α Quantakine kit    R&D Systems 
Human TGFβ1 Quantakine kit    R&D Systems 
Invasion chamber, pore size 8µm   BD Bioscience 
 
2.1.7 Plasmid 
pLOX/EW-iRES-EGFP lentivirus     Trono lab, Lausanne, CH 
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2.1.8 Chemicals and other reagents 
2-Mercaptoethanol     Sigma-Aldrich 
Bovine serum albumin (BSA)    Sigma-Aldrich 
DiI       Invitrogen, Molecular Probes 
DMSO       Sigma-Aldrich 
Glycine       Sigma-Aldrich 
Goat Serum      Sigma-Aldrich 
HCl       Sigma-Aldrich 
Hoechst 33342      Sigma-Aldrich 
Methanol      Sigma-Aldrich 
NaCl       Sigma-Aldrich 
Non-fat dried milk; bovine    Sigma-Aldrich 
Paraformaldehyde Solution    Sigma-Aldrich 
Polybrene transfection reagent    Millipore 
Recombinant human TGFβ1    R&D Systems 
SDS       MP Biomedicals 
TGFβ1 receptor kinase inhibitor SB431542  Sigma-Aldrich 
Tris base      Sigma-Aldrich 
Trypan blue      Sigma-Aldrich 
Tween ® 20      Invitrogen 
 
2.1.9 Software 
FACSDiva version 6.1.1     BD Biosciences 
Flow Jo 7.5.4      Tree Star, Inc. 
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Image J       http://rsbweb.nih.gov/ij/ 
NIS-Elements Basic Research    Nikon Instruments Inc. 
SPSS version 16.0     SPSS Science 
 
2.2 Cell biology methods 
 
2.2.1 Isolation and culture of human adipose tissue derived 
stem cells 
Unprocessed subcutaneous adipose tissue was obtained from patients undergoing elective 
body contouring procedures in accordance with the Institutional Ethical Review Board, 
Protocol Number ING_200601001 (“Human Subcutaneous Adipose Tissue for Cell Isolation 
Studies”). Freshly prepared adipose derived stromal cells were generously provided under 
Materials Transfer Agreement by Ingeneron, Inc., Houston, TX. 
For isolation of human adipose tissue derived stem cells (hASCs), tissue was minced and 
dissociated using Liberase Blendzyme 3 (F.Hoffman-La Roche Ltd) containing a mixture of 
highly purified collagenase and neutral protease enzymes at a concentration of 2 units/g 
tissue in phosphate-buffered saline (PBS; Cellegro) for 60 minutes at 37°C with intermittent 
shaking at 50 rpm. The digested tissue was then passed through a 100-μm filter (Millipore) 
and the floating adipocytes were separated from the stromal-vascular fraction by 
centrifugation at 1,000 rpm for 10 minutes. The cell pellet containing the target cells was 
washed twice with Hank’s balanced salt solution (HBSS; Cellegro) and finally re-suspended 
in alpha-modification of Eagle’s medium (αMEM; Cellegro) supplemented with 10% fetal 
bovine serum (FBS; Atlanta Biologicals), 2 mM L-glutamine (Cellegro), 100 U/ml penicillin 
and 100 μg/ml streptomycin (Cellegro). The plastic adherent adipose tissue derived stem 
cells were cultured on T75 tissue culture plates at 37°C in a humidified atmosphere (95% 
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humidity) containing 5% CO2. Daily washings with PBS removed the non-attached as well as 
the red blood cells. After three to five days hASCs were passaged using trypsin-
ethylenediaminetetraacetic acid (EDTA; Sigma-Aldrich) and plated in tissue culture flasks at 
a density of 1,000 cells/cm2. The complete process of cell isolation was carried out under 
sterile conditions in a laminar flow hood. The cell growth medium was changed every 3 
days and hASCs were subcultured every 4 to 5 days. Cells passaged for 2-5 population 
doublings (PDs) were used for all experiments (Fig. 2.1). 
 
 
 
 
 
 
 
 
 
 
All experiments were performed with hASCs isolated from three different donors (N=3) and 
each experiment was repeated at least three times (n=3). 
 
 
 
Figure 2.1 Human adipose tissue derived stem cells (hASCs) passage 3 in culture. 
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2.2.2 Flow cytometric analysis of CD surface markers on hASCs 
In order to characterize human ASCs, cells were labeled with either phyocoerythrin (PE)-
conjugated-antibodies or peridinin-chlorophyll (PerCP)-conjugated antibodies to target 
specific surface proteins. Subsequently the labeled cells were analyzed using flow 
cytometry and the distribution of the cells into different populations according to their 
specific emission intensity was displayed graphically. 
For flow cytometric analysis of phenotype in hASCs, cells in passage 3 were treated with 
0.05% trypsin-0.53 mM EDTA, washed twice with PBS and cell aliquots (1x105 cells/100µl) 
were stained with primary-conjugated antibodies at room temperature for 30 minutes in 
polystyrene round bottom tubes (Becton Dickinson Labware) in the dark. The conjugated 
antibodies used for these experiments were PE-conjugated anti-human CD14, CD29, CD34, 
CD90, CD105 and PerCP-conjugated anti-human CD44 and CD45 (all eBioscience). Normal 
mouse and rat IgG at the same concentrations as the primary antibodies were used as 
isotype-matched controls (all eBioscience). At least 1x104 events were counted for each 
sample using the fluorescence-activated cell sorter FACSCalibur (BD Biosciences) and data 
analysis was performed with Flow Jo 7.5.4 software (Tree Star, Inc.). 
 
2.2.3 Tumor cell lines 
In order to study the interactions between human adipose tissue derived stem cells and 
breast cancer cells in vitro the two distinct breast cancer cell lines MDAMB231 and MCF7 
were used in different settings. Both cell lines are of epithelial phenotype and originate 
from pleural effusion of adenocarcinoma of the breast. 
The human breast cancer cell lines MDAMB231 and MCF7 were purchased from the 
American Type Culture Collection and cultured in αMEM supplemented with 10% FBS, L-
glutamine, and penicillin-streptomycin at 37°C in a 5% CO2 containing chamber. The cell 
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growth medium was changed every 3 days and cancer cells were subcultured every 4 to 5 
days. 
 
2.2.4 Exposure of hASCs to tumor conditioned medium 
Tumor conditioned medium (TCM) from either MDAMB231 or MCF7 cancer cells was 
collected for further experiments in which hASCs were exposed to the cancer cell 
conditioned medium. 
TCM was collected from 90% confluent T175 flasks (8–10x106 cancer cells) of cancer cells 
after 24 h of incubation at 37°C with 25 ml of fresh, serum-free αMEM. The medium was 
then harvested, centrifuged at 3,000 rpm for 5 min at 4°C and passed through sterile 50 mL 
filtration system with 0.45-μm polyvinylidene difluoride membrane (Millipore). Conditioned 
medium (CM) was stored at -80°C in aliquots for subsequent use. hASCs were serum-
starved with 0% FBS αMEM for 24 hours and subsequently exposed to conditioned medium 
and the CM was changed every second day for the entire culturing period (24 h to 4 days). 
 
2.2.5 Direct co-culture of hASCs with cancer cells 
The interaction of breast cancer cells with human adipose tissue derived stem cells was 
studied in a direct co-culture system in vitro. 
The different cells were washed twice with PBS, digested with trypsin-EDTA and counted. 
Breast cancer cells (MDAMB231 or MCF7) and hASCs were co-seeded at a 2:1 ratio and 
grown to sub-confluence for immunofluorescence analysis (Fig. 2.2A and 2.2B). 
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Figure 2.2 (A) Breast cancer cell line MDAMB231 in direct co-culture with hASCs passage 3. 
Figure 2.2 (B) Breast cancer cell line MCF7 in direct co-culture with hASCs passage 3.  
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2.2.6 TGFβ1 treatment of hASCs 
In order to investigate the effect of human transforming growth factor beta 1 (TGFβ1) on 
the development of hASCs towards carcinoma-associated myofibroblasts, hASCs were 
stimulated with recombinant human TGFβ1 (rTGFβ1). 
Lyophilized recombinant human TGFβ1 (R&D Systems) was reconstituted in sterile 4 mM 
hydrogen chloride (HCl) containing 0.1% BSA to prepare a stock solution 10 μg/mL and used 
for the treatment of hASCs. Before use, cells grown in regular medium containing 10% FBS 
were deprived of serum using serum-free medium for 24 hours. This was followed by 
incubation of the cells with serum-free medium containing 0.2 or 2 ng/ml rTGFβ1 for up to 
4 days at 37°C in a humidified atmosphere containing 5% CO2. The recombinant TGFβ1 
treated hASCs were subsequently used for further experiments. 
 
2.2.7 TGFβ receptor kinase inhibition and anti-TGFβ1 
treatment 
For inhibition of the TGFβ Type 1 receptor-like kinase, cells were pre-incubated with 
SB431542 (10 μM; Sigma-Aldrich) for 30 min. Pre-incubation with dimethylsulfoxide 
(DMSO) as a vehicle for the same time was used as a control.  
To neutralize TGFβ1, cells were cultured in the presence of 0.2 µg/ml anti-TGFβ1 
neutralizing-antibody (R&D Systems; Catalog Number: AF-101-NA). Normal chicken IgY 
(R&D Systems; Catalog Number: AB-101-C) at the same concentration was used as a 
control. 
 
2.2.8 Cell staining 
2.2.8.1 Immunofluorescence analysis 
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The cells subject to immunofluorescence analysis were grown to subconfluence in 6-well 
plates with growth medium containing 10% FBS, and then deprived of serum by rinsing 
three times with PBS and incubating with serum-free medium (αMEM containing 2 mM L-
glutamine, 100 U/ml penicillin and 100 μg/ml streptomycin) for 24 hours. The serum-
starved cells were treated under appropriate conditions, washed twice with PBS, fixed in 
4% paraformaldehyde (PFA) for 10 min at room temperature, washed twice with PBS and 
blocked with 10% goat serum (Sigma-Aldrich) at room temperature for 10 minutes. 
Subsequently the cells were incubated with primary antibodies using anti-alpha smooth 
muscle actin (dilution 1:250; Clone 1A4; Sigma-Aldrich) or anti-tenascin-C (dilution 1:250; 
Clone BC-24) antibodies for 1 hour at room temperature or at 4°C overnight in the cold 
room. Following further washing the cells were incubated with Alexa Fluor 488-conjugated 
goat anti-mouse secondary antibody (Invitrogen, Molecular Probes) for 1 h at a dilution of 
1:500 in the dark.  
For TGFβ type II receptor staining, the cells were stained with a fluorescein conjugated anti-
TGFβ RII antibody (1:50; Clone H-567; Santa Cruz Biotechnology). 
Finally all cells were washed twice with PBS, counterstained with the nuclear dye Hoechst 
33342 (Sigma-Aldrich) and examined with a fluorescence microscope. Pictures were taken 
at a 10 or 20-fold magnification. 
hASCs cultured under different conditions were quantified for the expression of alpha 
smooth muscle actin (α-SMA) and cells staining positive for α-SMA were counted as a 
fraction of the total cell number (at least 70 cells were counted per view field) in nine 
independent view fields in each group at a 10x magnification under the microscope. For 
each group at least 630 cells were counted. The experiments were repeated at least three 
times. 
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2.2.8.2 DiI staining 
The hydrophobic cyanine dye DiI (1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine 
perchlorate) allows fast and easy fluorescent cell labeling. 
For cell staining, 80% confluent T25 flask of MDAMB231 cells were incubated with 3 ml of 
their regular culture medium containing 15 μl of DiI (Invitrogen, Molecular Probes) for 1 
hour at 37°C in a humidified atmosphere containing 5% CO2. Cells were washed twice with 
PBS and regular medium was added for 5 minutes. This procedure was repeated twice and 
after that cells were harvested and seeded for the following experiment. 
 
2.2.8.3 GFP labeling of MDAMB231 cells 
For stable green fluorescence protein (GFP) labeling of MDAMB231 cancer cells, 5x104 cells 
per well were seeded in 6-well tissue culture plates in the presence of 2 ml of αMEM. 
Lentiviral GFP transfection was performed with a plox/EW-iRES-EGFP lentivirus (Trono lab, 
Lausanne, CH) and polybrene (hexadimethrine bromide) was used in a concentration of 8 
µg per ml to increase the efficiency of transfection. The cells were incubated with 
transfection medium for 24 h at 37°C in a humified atmosphere containing 5% CO2 
whereupon the medium was replaced using 2ml of fresh αMEM per well. After three weeks 
of keeping the transfected cells in αMEM with weekly medium changes, fluorescence-
activated cell sorting was performed at MD Anderson cancer center core facility. GFP-
labeled MDAMB231 cancer cells were sorted using the BD FACSAria II cell sorter and 
FACSDiva Version 6.1.1 software. GFP-positive cells were subsequently cultured in 10% FBS 
αMEM until used for invasion assay. 
 
2.2.9 Invasion assay 
Invasion assays allow studying the potential of cells to invade extracellular matrix (ECM) 
and offer a valuable tool to quantify the invasion potential of cancer cells in vitro. 
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The invasion potential of MDAMB231 cancer cells was evaluated using a Boyden chamber 
with filter inserts (pore size 8 μm) coated with matrigel basement membrane matrix in 24-
well dishes (BD Biosciences). The matrigel matrix, which consists mainly of laminin and 
collagen IV, functions as a reconstituted basement membrane in vitro. According to the 
manufacturer’s protocol the invasion chambers were allowed to come to room 
temperature (RT) for an hour. Then PBS was added and the chambers were rehydrated for 
2 h at 37°C. 35x103  DiI-stained or GFP-labeled MDAMB231 cancer cells were seeded alone 
or in co-culture with hASCs (70x103 cells/well) pre-exposed to TCM or recombinant human 
TGFβ1 (0.2 ng/ml) for 4 days in 600 μl of αMEM 5% FBS in the upper chamber. The lower 
chamber contained αMEM 10% FBS. For invasion assays of MDAMB231 cancer cells with 
conditioned medium, 35x103 cancer cells per well were seeded with CM from hASCs 
treated under appropriate conditions. For preparation of hASC-CM, cells were pretreated 
with 10 µM SB431542 or DMSO as a vehicle for 30 min and then cultured in serum free 
medium, 0.2 ng/ml recombinant human TGFβ1 (rTGFβ1; R&D Systems), or MDAMB231-CM 
over 4 days. The medium was then changed to αMEM 5% FBS and conditioned for 72h 
before use. For all invasion assays the chambers were incubated for 40 h at 37°C in 5% CO2 
and non-invaded cells were removed from the top surface of the insert by scrubbing with 
cotton tip swabs and the filters were rinsed with PBS. Invaded cells were fixed on the 
membrane in 5% PFA, washed twice with PBS and counterstained with Hoechst 33342 dye 
as a nuclear stain. Invaded DiI + Hoechst 33342 positive cancer cells on the underside of the 
filters were counted in five independent view fields at 20x magnification of each insert 
under the microscope. For invasion assays with GFP-labeled MDAMB231 the cells were not 
counterstained Invaded GFP-positive cells on the underside of the filters were equally 
counted under the microscope. 
 
2.2.10 FACS analysis of hASCs 
As a specialized type of flow cytometry, fluorescence-activated cell sorting (FACS) provides 
a fast method for sorting a heterogeneous mixture of cells. Based upon the specific 
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fluorescent and light scattering characteristics of each cell the heterogeneous cell-mixture 
can be sorted into two or more containers at a time. 
For FACS analysis of tenascin-C in hASCs, cells were grown to subconfluence (60%) in T175 
flasks with growth medium containing 10% FBS. Subsequently 5-7x105 cells were incubated 
with serum-free medium for 24 h. The serum-starved cells were afterwards treated for 4 
days under appropriate conditions, harvested, washed twice with PBS and cell aliquots 
were incubated with 5 µg/ml anti-tenascin-C antibody (R&D Systems, clone 578) for 20 
minutes. Following further washing the cells were incubated with Alexa Fluor conjugated 
goat anti-rat IgG secondary antibody (1:200; R&D Systems) for 20 min, washed twice with 
PBS and used for FACS analysis to separate tenascin-C positive from tenascin-C negative 
cells. The MD Anderson cancer center core facility was used to sort the cells using the BD 
FACSAria II cell sorter and FACSDiva Version 6.1.1 software. Positive and negative tenascin-
C cells were then cultured separately in 10% FBS αMEM over 4 days. For further 
experiments conditioned medium was collected from approximately 5 million cells of each 
group and used for chemokine C-C motif ligand 5 (CCL5) ELISA using the CCL5 Quantikine kit 
(R&D Systems). Each experiment was repeated at least three times. 
 
2.3 Molecular biology methods 
 
2.3.1 Enzyme-linked immunosorbent assay 
The quantitative sandwich enzyme immunoassay technique was used for the determination 
of the concentrations of human stromal cell-derived factor 1 alpha (SDF-1α), CCL5 and 
TGFβ1 in cell culture supernates. 
Enzyme-linked immunosorbent assay (ELISA) was performed using the human TGFβ1, SDF-
1α and CCL5 Quantikine kit (R&D Systems; Catalog Number: DB100B, DSA00 and DRN00B) 
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according to the manufacturer’s description and experiments were repeated at least three 
times. Cells were treated under appropriate conditions and cell culture supernatants were 
collected, centrifuged and filtered through a 0.45-μm Steriflip Filter Unit (Millipore). 
Standards, samples and controls were pipetted into the wells of a pre-coated microplate 
containing monoclonal antibodies specific for SDF-1α, TGFβ1 or CCL5 respectively. Any SDF-
1α, TGFβ1 or CCL5 present in the specific samples was thereby bound to the immobilized 
antibodies. After 2 hours of incubation any unbound substances were washed away and a 
specific enzyme-linked polyclonal antibody was added to the wells. Following further 
washing, a substrate solution was added to the wells in the dark and the intensity of the 
developing color was measured. The absorbance (450nm) for each sample was analyzed by 
an ELISA reader (Spectrophometer µQuant; BioTek Instrumentes) and interpolated with a 
standard curve. 
 
2.3.2 Western blot analysis 
The expression levels of Smad2, Smad3, phosphorylated Smad2 and Smad3, α-SMA and β-
Actin in different samples of hASCs were determined by western blot analysis. 
Serum-starved hASCs were treated under appropriate conditions, washed with ice-cold PBS 
and cells were re-suspended in lysis buffer (Cell Signaling), including protease inhibitor 
cocktail (Roche Diagnostics) according to the vendor´s protocol. The samples were heat-
blocked at 95°C for 5 minutes and 24 μg protein-extract/sample was run on pre-cast SDS 
PAGE 4-15% Tris-HCl gels (BioRad) in electrophoresis running buffer 10xTris/glycine/SDS 
(BioRad) using the BioRad Mini-Protean® Tetra Cell system. Gels were run at 70V for 30 
minutes and then for up to 1 hour at 100V until the loading dye had run out. 
Subsequently the gels were transferred onto polyvinylindene difluoride (PVDF) membranes 
(Millipore) soaked in 1x transfer buffer (40 mM Tris-HCl, 39 mM Glycine, 1.3 mM SDS, 20% 
Methanol) using a semi-dry blotting device (BioRad) at 0.18A and 24V for 2 hours. 
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The membranes were washed briefly and after blocking with 5% nonfat milk in 1x Tris 
buffered saline (TBS) with Tween® 20 (polyoxyethylenesorbitan monolaurate) for 1 h at 
room temperature the primary antibody was applied. Primary antibodies were diluted in 
5% nonfat milk/1x TBS with Tween® 20 (TBST) and membranes were incubated with 
antibody mixtures overnight at 4°C on a shaker. The primary antibodies used were anti-
phospho-Smad2 (dilution 1:1000; Cell Signaling, catalog # 3101), anti-Smad2 (1:1000; Cell 
Signaling, catalog #3122), anti-phospho-Smad3 (1:1000; Epitomics, clone EP823Y), anti-
Smad3 (1:1000; Abcam, clone EP568Y), anti- α-SMA (1:400, Abcam, clone E184) and anti-β-
Actin (1:1000; Sigma-Aldrich, clone AC15). Membranes were probed with corresponding 
HRP-conjugated secondary antibodies (1:2000; Cell Signaling) in 5% nonfat milk /1x TBS 
with Tween® 20 and incubated for 1 h at RT under agitation. The membranes were washed 
with TBST six times for five minutes under agitation and then incubated in ECLTM detection 
solution (GE Healthcare) for 1 minute. Finally the membranes were transferred to a 
western blot cassette and exposed to BioMaxTM MR single-emulsion film (Sigma-Aldrich). 
Image J software was used to determine the average density of western blot protein bands. 
The experiments were repeated at least three times independently. 
 
2.4 Statistical analysis 
All results are presented as means ± standard deviations (SD). All experiments were 
repeated at least three times independently from each other. For statistical analysis, the 
Student’s t test was performed using SPSS 16.0 software. Probability values were calculated 
two-sidede and considered to be statistically significant with a value of P≤0.05. 
 
Results 
 
32 
3. Results 
 
3.1 Flow cytometric analysis of phenotype in 
hASCs 
Flow cytometric analysis was performed on three different samples in passage 3 in order to 
characterize the surface antigens of human adipose tissue derived stem cells (hASCs). The 
phenotype of hASCs was analyzed for different antibodies typically expressed by 
mesenchymal stem cells. Flow cytometric analysis revealed that hASCs were positive for the 
mesenchymal stem cell markers CD29, CD44, CD90 and CD105. The cells were negative for 
CD14, CD34 and CD45, which excludes contamination with hematopoietic cells (Fig. 3.1). 
 
 
 
 
 
 
 
 
 
Figure 3.1  hASCs express CD surface markers typical for mesenchymal stem cells. Flow 
cytometric characterization of CD surface markers on hASCs. Black histograms indicate isotype-
matched controls; red histograms show surface antigen expression level.  
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3.2 hASCs within the breast cancer tumor 
microenvironment 
In order to explore whether hASCs could be a potential source of myofibroblasts within the 
tumor microenvironment of breast cancer, the direct and indirect interactions of hASCs 
with the two breast cancer cell lines MDAMB231 and MCF7 was studied in vitro. The 
question was addressed by looking at the phenotype of hASCs and if this initial phenotype 
might change to a more specific myofibroblast-like one under the influence of the tumor 
microenvironment.  
 
3.2.1 hASCs express myofibroblast markers in co-culture with 
breast cancer cells 
In order to explore whether hASCs could be a potential source of myofibroblasts, a direct 
co-culture system of hASCs with MDAMB231 or MCF7 breast cancer cells had been 
established as a starting point. Stem cells were always co-seeded with MDAMB231 or MCF7 
at a 2:1 ratio and cultured in serum-free αMEM medium over 4 days (Fig. 3.2a and 3.2b). 
Myofibroblast-like cells were detected by immunofluorescence (IF) staining using an 
antibody against alpha smooth muscle actin (α-SMA) which is a specific myofibroblast 
marker. Immunofluorescence staining revealed that hASCs contained only a small number 
of α-SMA positive cells when grown in mono-culture over 4 days. MDAMB231 or MCF7 
breast cancer cells alone did not contain any α-SMA positive cells after 4 days in culture. 
Interestingly, the number of α-SMA positive cells increased significantly after co-culturing 
hASCs with MDAMB231 or MCF7 cells for 4 days, suggesting that hASCs differentiated into 
myofibroblast-like cells in this co-culture system (Fig. 3.2c-3.2f). 
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3.2.2 Tumor cell conditioned medium induces the expression of 
myofibroblast markers in hASCs 
In order to investigate if the expression of myofibroblast markers in hASCs does only take 
place when direct cell-cell interactions are allowed (Fig. 3.2) or if humoral factors might be 
involved in this process through paracrine communications, hASCs alone were cultured in 
breast cancer cell conditioned medium (CM). Tumor cell conditioned medium (TCM) was 
obtained from either MDAMB231 or MCF7 cancer cells as described in the materials & 
methods section (see 2.2.4 for details). Briefly, TCM was collected from confluent flasks of 
cancer cells after 24 h of incubation in serum-free medium, filtered and directly used for 
further experiments or stored at -80°C. hASCs in culture (passage 2-4) were serum-starved 
with serum-free medium for 24 h, exposed to TCM for 4 days and subsequently stained 
with either α-SMA or tenascin-C, another specific myofibroblast marker. IF staining 
revealed that the majority of hASCs had acquired a myofibroblast phenotype (expression of 
α-SMA and tenascin-C) after culturing for 4 days in TCM, indicating that breast cancer cell 
derived humoral factors are involved in the differentiation (Fig. 3.3). 
Figure 3.2  Direct co-culture of hASCs with breast cancer cells. (a, b) Brightfield pictures of direct 
co-culture of MDAMB231 cells or MCF7 cells with hASCs grown in serum-free medium over 4 
days. The co-culture of hASCs with (c) MDAMB231 or (d) MCF7 and monocultures of either (e) 
MDAMB231, (f) MCF7 or (g) hASCs were grown 4 days in serum-free medium and the expression 
of α-SMA (green channel) was determined by immunostaining with an anti α-SMA antibody. 
Nuclei were counterstained with Hoechst 33342 and appear blue. Scale bar, 100 μm. 
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3.2.3 The induction of α-SMA in hASCs is time-dependent 
In order to quantify the expression of α-SMA in TCM-stimulated hASCs the percentage of 
cells expressing α-SMA was determined at different time points. Immunostaining was 
performed as described above (see 2.2.8.1 in materials & methods section) and α-SMA 
positive cells were counted as a fraction of the total cell number in nine randomly chosen, 
independent view fields in each group at a 10x magnification under the microscope. 
The differentiation of hASCs towards myofibroblast-like cells was time-dependent. After 
culturing hASCs with TCM for 1 day, only 2.0% ± 0.3% (hASCs cultured in MDAMB231 CM) 
and 3.0% ± 0.8% (hASCs cultured in MCF7 CM) of the cells expressed α-SMA, whereas 
52.0% ± 11.2% (hASCs cultured in MDAMB231 CM) and 50.5% ± 3.7% (hASCs cultured in 
MCF7 CM) of the cells expressed α-SMA after 4 days (Fig. 3.4). 
 
Figure 3.3  Immunofluorescence staining of hASCs for myofibroblast markers. (a, d) hASCs were 
cultured in serum-free medium or with serum-free tumor conditioned medium from either (b, e) 
MDAMB231 or (c, f) MCF7 cancer cells for 4 days and stained with (a-c) anti α-SMA and (d-f) anti 
tenascin-C antibodies, respectively. Scale bar, 100 μm. 
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Figure 3.4  Quantitative analysis of the expression of α-SMA in hASCs. α-SMA in hASCs cultured 
for 1 or 4 days in either MDAMB231 or MCF7 serum-free conditioned medium or serum-free 
medium alone was determined by immunofluorescence analysis (see materials & methods for 
details).* indicates P<0.0001 as compared to hASC alone on day IV. 
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3.3 Influence of breast cancer-cell derived TGFβ1 
on the differentiation of hASCs 
hASCs stimulated with tumor conditioned medium expressed a significant number of α-
SMA positive cells (Fig. 3.4) which is a main marker for myofibroblasts. Furthermore it was 
investigated which breast cancer cell derived humoral factors could be involved in the 
differentiation of hASCs towards myofibroblast-like cells.  
 
3.3.1 MDAMB231 and MCF7 breast cancer cells secrete TGFβ1 
It is known that α-SMA expression can be induced by stimulation with exogenously added 
transforming growth factor beta 1 (TGFβ1) in quiescent human breast gland fibroblasts 
(Ronnov-Jessen and Petersen, 1993). Hence the possible involvement of TGFβ1 in the 
signaling pathway of human adipose tissue derived stem cells towards α-SMA positive cells 
was studied.  
In a first step the question was raised whether the two breast carcinoma cell lines 
MDAMB231 and MCF7 secrete TGFβ1, which could be involved in myofibroblast 
differentiation of hASCs. Hence MDAMB231 and MCF7 were cultured in αMEM without 
addition of FBS (which might by itself contain TGFβ) and conditioned medium from these 
cells was collected after 0, 24 and 48 hours for the detection of TGFβ1 protein levels by 
enzyme-linked immunosorbent assay (ELISA). As shown in Figure 3.5, a significant amount 
of TGFβ1 (204.9 ± 31.9 pg/ml in CM from MDAMB231 and 283.3 ± 24.8 pg/ml in CM from 
MCF7) was detected in the medium after 24 hours conditioning time and TGFβ1 secretion 
from MDAMB231 and MCF7 reached a maximum level after 48 hours in culture (291.1 ± 7.3 
and 666.7 ± 47.2 pg/ml respectively). On the other hand TGFβ1 was not detected in 
conditioned medium from hASCs cultured for 24 and 48 hours (Fig. 3.5). Serum-free αMEM 
medium was used as a negative control for ELISA and did not contain any TGFβ1. 
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Figure 3.5  Tumor conditioned medium contains TGFβ1. The amount of TGFβ1 in serum-free 
medium or serum-free conditioned medium from MDAMB231, MCF7 and hASCs was measured 
by ELISA at different time points. Data represent mean ± SD. (n=3). *P indicates <0.0001 as 
compared to serum-free medium.  
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3.3.2 TGFβ type II receptor is expressed in hASCs 
It is known that TGFβ1 induces α-SMA expression through binding to its type II receptor and 
subsequent phosphorylation and activation of Smad2 and Smad3 (Hu et al., 2003; 
Massague, 2008). Since TCM contained significant amounts of TGFβ1 (Fig. 3.5) the next step 
was to investigate whether hASCs might express the corresponding receptor. 
Immunofluorescence staining of hASCs with a fluorescein conjugated anti-TGFβ type II 
receptor antibody (TGFβ RII) revealed that hASCs do indeed expresse the receptor (Fig. 3.6) 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.6  Immunofluorescence staining of hASCs with a fluorescein conjugated anti-TGFβ type 
II receptor antibody (green channel). Nuclei were counterstained with Hoechst 33342 and 
appear blue in the photograph. Scale bar, 50 μm 
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3.3.3 Breast cancer cell-derived TGFβ1 induces α-SMA 
expression in hASCs through Smad2/3 signaling 
Phosphorylation of the transcription factors Smad2 and Smad3 are key components in 
intracellular signaling of TGFβ1 (Shi and Massague, 2003). To further prove whether TGFβ is 
involved in myofibroblast differentiation of hASCs, protein levels of phosphorylated Smad2 
and Smad3 (p-Smad2, p-Smad3) and α-SMA in stimulated hASCs were measured using 
western blot analysis. In a first set of experiments protein levels of Smad3 (molecular 
weight 58kDa), p-Smad3 (58kDa), α-SMA (42kDa) and β-Actin (42kDa, used as a loading 
control) were measured in TCM-activated or TGFβ1-stimulated hASCs. Non-stimulated 
hASCs cultured in serum-free medium over 4 days were used as a control. Western blot 
analysis demonstrated that hASCs expressed higher protein levels of p-Smad3 and α-SMA 
after exposure to CM from MDAMB231 (0%FBS; 24 h conditioning time) over 4 days 
compared to hASCs cultured in regular, serum-free medium (Fig. 3.7A). Similarly, hASCs 
cultured in serum-free medium supplemented with 0.2 ng/ml recombinant TGFβ1 over 4 
days revealed strong phosphorylation of Smad3 and high protein levels of α-SMA. The 
different protein expression levels of p-Smad3 in stimulated and non-stimulated hASCs 
were confirmed by measuring the average density of the western blot protein bands of p-
Smad3 with Image J software. The up-regulation of p-Smad3 in stimulated hASCs as 
compared to non-stimulated control hASCs was graphically displayed as fold induction of p-
Smad3 and is shown in Figure 3.7B. 
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These experiments illustrate that phosphorylation of Smad3 can be induced by exogenously 
added TGFβ1 as well as by breast cancer cell conditioned medium, indicating that TGFβ1 
present in TCM is responsible for the activation of p-Smad3 in TCM-stimulated hASCs. 
In a further step it was explored if the inhibition of the TGFβ1 signaling pathway in hASCs 
would result in a reduced phosphorylation of the transcription factors Smad2 and Smad3 
and would consequently lead to lower protein levels of α-SMA. For inhibition of the TGFβ1 
activin receptor-like kinase receptors in hASCs, cells were pretreated for 30 minutes with 
dimethylsulfoxide (DMSO) as a vehicle or 10 µM SB431542 which is a selective and potent 
inhibitor specifically of activin receptor-like kinase 4, 5 and 7 (ALK4, ALK5 and ALK7). The 
Figure 3.7  Induction of p-Smad3 in stimulated hASCs. (A) hASCs were exposed to either serum-
free medium alone, MDAMB231 CM (0% FBS; 24 h conditioning time), or serum-free medium 
containing 0.2 ng/ml recombinant TGFβ1 over 4 days. The expression levels of Smad3, 
phosphorylated Smad3 (p-Smad3), α-SMA and β-Actin were determined by western blot analysis 
using anti-Smad3, anti-p-Smad3, anti-α-SMA and anti-β-Actin antibodies. β-Actin was used as a 
loading control. (B) The induction of p-Smad3 in stimulated hASCs was analyzed by measuring the 
density of p-Smad3 western blot protein bands and displayed as fold induction normalized to non-
stimulated control hASCs. P<0.0001 as compared to control hASCs. 
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cells were then exposed to serum-free medium as a control group or MDAMB231 CM 
(0%FBS; 24 h conditioning time). To neutralize TGFβ1, cells were cultured in MDAMB231 
CM (0%FBS; 24 h conditioning time) over 4 days in the presence of 0.2 µg/ml anti-TGFβ1 
neutralizing-antibody. The protein levels of Smad2 (molecular weight 60kDa), p-Smad2 
(60kDa), Smad3, p-Smad3, α-SMA and β-Actin were measured by western blot analysis. 
Both TGFβ activin receptor-like kinase receptor inhibition with SB431542 as well as anti-
TGFβ1 treatment with the neutralizing antibody markedly reduced the phosphorylation of 
Smad2 (Fig. 3.8A) and Smad3 (Fig. 3.8B). Notably, the inhibition of the TGFβ1 signaling 
pathway did also significantly reduce protein levels of α-SMA in hASCs (Fig. 3.8). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.8  Inhibition of Smad2/3 phosphorylation and α-SMA expression. hASCs were pretreated 
with DMSO as a vehicle or 10 μM SB431542 (TGFβ1 activin receptor-like kinase receptor 
inhibitor) for 30 minutes and then exposed to serum-free medium (control) or MDAMB231 CM 
for 4 days. To neutralize TGFβ1, cells were cultured in TCM for 4 days in the presence of anti-
TGFβ1 neutralizing-antibody (0.2 μg/ml). The expression levels of (A) Smad2, phosphorylated 
Smad2, (B) Smad3, phosphorylated Smad3, α-SMA and β-Actin were determined by western blot 
analysis. 
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To further confirm the role of TGFβ1 in hASC differentiation towards myofibroblasts, hASCs 
were treated with different concentrations of recombinant human TGFβ1 or TCM from 
MCF7 and MDAMB231 cancer cells for 4 days and the percentage of cells expressing α-SMA 
was quantified by immunofluorescence analysis as described in previous experiments (see 
3.2.3). After stimulation with 0.2 ng/ml rTGFβ1 50.6% ± 3.2% of the cells expressed α-SMA, 
whereas after stimulation with 2 ng/ml rTGFβ1 75.2% ± 7.5% of the cells expressed the 
myofibroblast marker, indicating that exogenously added TGFβ1 dose-dependently 
increased the expression of α-SMA in hASCs (Fig. 3.9). Furthermore, it was shown that 
treatment with 0.2 ng/ml recombinant TGFβ1 over 4 days, which is approximately the 
amount of TGFβ1 secreted by MDAMB231 cells after 24 hours (as determined by ELISA 
within the established experimental setup [see Fig. 3.5], elicited a stem cell response 
indistinguishable from that obtained with TCM (0% FBS; 24 h conditioning time) (Fig. 3.9). 
Additionally, abrogation of TGFβ1-dependent activity was achieved using a neutralizing 
antibody against TGFβ1 (0.2 µg/ml) in both hASCs cultured with 0.2 ng/ml rTGFβ1 and in 
hASCs cultured in MDAMB231 CM (Fig. 3.9). Cells treated with rTGFβ1 in the presence of 
anti-TGFβ1 over 4 days expressed only 3.7% ± 2.0% α-SMA positive cells. Cells cultured in 
MDAMB231 CM in the presence of anti-TGFβ1 over 4 days expressed only 8.2% ± 1.2% α-
SMA positive cells. hASCs cultured in MDAMB231 CM in the presence of normal chicken IgY 
over 4 days were used as a control group and expressed 50.3% ± 3.5% α-SMA-positive cells 
in line with previous experiments. 
Furthermore, the percentage of TCM-induced expression of α-SMA (both by MDAMB231 
CM as well as MCF7 CM) was markedly reduced by pretreatment of hASCs with the TGFβ1 
activin receptor-like kinase receptor inhibitor (Figure 3.9). Cells pretreated with 10 µM 
SB431542 for 30 minutes and consequently stimulated with TCM over 4 days expressed 
significantly less α-SMA positive cells than those pretreated with a vehicle (DMSO) for 30 
minutes in the corresponding control group. 
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These immunofluorescence analysis results confirm the findings of the previous western 
blot analysis (Fig. 3.7 and 3.8) and together clearly indicate the involvement of cancer-cell 
derived TGFβ1 in the differentiation of hASCs towards myofibroblast-like cells. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.9  TGFβ1 is critical to hASC-differentiation towards myofibroblast-like cells. Serum-
starved hASCs were treated with different concentrations of recombinant TGFβ1 (0.2 and 2 
ng/ml) or cultured in MDAMB231 conditioned medium (0% FBS; 24 h conditioning time) for 4 
days in the presence of anti-TGFβ1 neutralizing antibody (0.2 μg/ml) or control normal chicken 
IgY (0.2 μg/ml). For inhibition of TGFβ1 receptor kinases hASCs were pretreated with 10 μM 
SB431542 or DMSO as a vehicle for 30 minutes and then exposed to CM from either MDAMB231 
or MCF7 cancer cells for 4 days. The quantitative expression of α-SMA in hASCs was analyzed by 
immunofluorescence staining and cells positive for α-SMA were counted as a fraction of the total 
cell number in each group. Data represent average values ± SD. (n=3). * indicates P<0.0001, ** 
indicates P<0.0004. 
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3.4 Secretion of SDF-1α from stimulated hASCs 
In breast cancer a key feature of tumor activated myofibroblasts is their potential to 
stimulate tumor growth and to promote angiogenesis partially through their ability to 
secrete stromal cell-derived factor 1 (SDF-1α) (Orimo et al., 2005). To further prove that 
hASCs acquire a myofibroblast-like profile under the influence of breast carcinoma cell-
derived chemokines it was examined whether stimulation with MDAMB231 and MCF7 CM 
could induce SDF-1α protein production in hASCs. 
 
3.4.1 Secretion of SDF-1α from hASCs increases upon 
stimulation with TCM 
For the detection of stromal cell-derived factor 1 alpha, hASCs were cultured in TCM 
(0%FBS, 24 h conditioning time) of MDAMB231 or MCF7 cancer cells. Cell culture 
supernatant from these hASCs was analyzed by ELSIA after 12, 24, 48 and 72 hours. ELISA 
testing indicated that the secretion of SDF-1α from TCM-activated hASCs was time-
dependent, reaching a maximum level after 72 hours in culture for both hASCs cultured in 
MCF7 and MDAMB231 CM (Fig. 3.10). Stimulation with conditioned medium from 
MDAMB231 cells caused a significantly higher production of SDF-1α than stimulation with 
MCF7 CM (742.3 ± 37.6 pg/ml as compared to 176.1 ± 7.8 pg/ml after 72 h). As shown in 
Figure 3.11, the increase in SDF-1α protein-level after 72h was 5.2-fold for hASCs cultured 
in MDAMB231 CM as compared to the control group of hASCs cultured in serum-free 
regular medium (P<0.001). 
 
 
 
 
Results 
 
46 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.4.2 Influence of TGFβ1 on SDF-1α secretion 
Additionally the involvement of TGFβ1 in the production of SDF-1α was analyzed. Serum-
starved hASCs were incubated with the TGFβ1 receptor kinases inhibitor SB431542 or 
DMSO as a vehicle for 30 minutes, cultured in MDAMB231 conditioned medium (0%FBS, 24 
h conditioning time) or serum-free αMEM for 72 h and subsequently cell culture 
supernatants were subjected to SDF-1α ELISA. As shown in Figure 3.11, the increased 
Figure 3.10  TCM stimulates the secretion of SDF-1α from hASCs. Protein levels of SDF-1α secreted 
from hASCs exposed to either MCF7 (blue bars) orMDAMB231 (red bars) conditioned medium 
(0%FBS, 24 h conditioning time) over time was measured by ELISA. The experiment was repeated 
three times. *P<0.0001 and **P<0.002 versus 12 h TCM (MCF7 and MDAMB231 CM respectively). 
 
Results 
 
47 
expression of SDF-1α in TCM-activated hASCs was significantly reduced by pretreatment 
with SB431542 (417.8±74.5 pg/ml as compared to 792.3±129.8 pg/ml; P<0.01). 
Interestingly, 72 h stimulation with recombinant TGFβ1 did not affect the secretion of SDF-
1α from hASCs (Fig. 3.11), suggesting that TGFβ1 alone cannot be sufficient for the TCM-
induced production of SDF-1α, although the TGFβ1 signaling pathway seems to be involved 
in SDF-1α secretion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.11  Effect of 
TGFβ1 on SDF-1α in 
hASCs. Serum-starved 
hASCs were pretreated 
with a vehicle (DMSO) or 
10 μM SB431542 (TGFβ1 
kinases inhibitor) for 30 
min and then cultured in 
serum-free medium, 
MDAMB231 CM or 
exposed to 0.2 ng/ml 
rTGFβ1 for 72 hours. 
Cell culture 
supernatants were 
subjected to ELISA for 
the measurement of 
SDF-1α protein levels. 
*P<0.001, **P<0.01. 
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3.5 Secretion of CCL5 from TCM-activated hASCs 
In a further step the question was raised whether the secretion of the chemokine CCL5 
which is known to be involved in breast cancer progression (Soria and Ben-Baruch, 2008) 
was increased in hASC-derived myofibroblasts. CCL5 had already been identified as a hASC-
derived humoral factor that can promote breast cancer cell invasion in vitro in a previous 
study (Pinilla et al., 2009). 
For detection of hASC-derived myofibroblast-like cells the expression level of tenascin-C in 
TCM-activated and normal hASCs was determined using fluorescence-activated cell sorting 
(FACS). Hence hASCs were cultured in either MDAMB231 CM (0% FBS; 24 h conditioning 
time) or serum-free regular growth medium over 4 days, incubated with 5 µg/ml anti-
tenascin-C antibody and Alexa Fluor conjugated secondary antibody and subsequently 
separated by fluorescence-activated cell sorting. FACS sorting analysis revealed that after 4 
days in tumor conditioned medium 24.8% of the cells expressed tenascin-C whereas only 
0.4% of the cells cultured in serum-free regular medium for the same time expressed this 
myofibroblast marker (Fig. 3.12b and 3.12c). 
The separated cell fractions of tenascin-C positive and negative cells previously cultured in 
MDAMB231 conditioned medium over 4 days were subsequently cultured in regular growth 
medium (αMEM containing 10%FBS) over 4 days and cell culture supernatants were 
analyzed by ELISA for CCL5 protein levels using the human CCL5 Quantakine kit. 
Interestingly, cells positive for tenascin-C produced significantly more CCL5 than the 
tenascin-C negative cell fraction (744.13 ± 67.95 as compared to 217.38 ± 21.95 pg/500,000 
cells; Figure 3.13). These results confirmed that hASCs cultured in tumor conditioned 
medium partially differentiate into tenascin-C positive myofibroblasts as shown by IF 
staining (see Fig. 3.3) and additionally demonstrated that these differentiated cells produce 
elevated levels of the chemokine CCL5. 
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Figure 3.12  FACS sorting analysis of hASCs for 
tenascin-C. Serum-starved hASCs were cultured in 
MDAMB231 conditioned medium (0% FBS; 24 h 
conditioning time) or serum-free regular growth 
medium over 4 days and subsequently sorted 
with FACS using an anti-tenascin-C antibody 
(5µg/ml). Green dots in population P4 indicate 
tenascin-C negative cell counts; red dots in 
population P5 indicate tenascin-C positive cell 
counts. Representative diagrams show cell counts 
from (b) FACS sorting of hASCs cultured in serum-
free regular growth medium over 4 days (0.4% 
positive tenascin-C cells) and (c) hASCs grown in 
MDAMB231 CM over 4 days (24.8% positive 
tenascin-C cells). (a) Unstained hASCs were used 
as negative control for cell sorting. 
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Figure 3.13  Tenascin-C positive hASC-derived myofibroblasts produce elevated levels of CCL5. Cell 
fractions of tenascin-C positive and negative cells previously cultured in MDAMB231 CM as sorted 
by FACS were cultured in regular growth medium over 4 days and cell culture supernatant from 
these cells was used for the detection of CCL5 protein levels by ELISA. Data represent mean ± SD. 
Experiments were repeated three times. * indicates P<0.0003. 
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3.6 Invasion of MDAMB231 cancer cells in vitro 
An important feature of tumor-activated myofibroblasts is their ability to promote cancer 
cell invasion (De et al., 2004). An in vitro invasion assay was established in order to assess 
the impact of hASC-derived myofibroblasts on the invasion of breast cancer cells. The 
matrigel matrix of the invasion assay consists mainly of laminin (56%) and collagen IV (31%) 
and functions as a reconstituted basement membrane in vitro. In order to invade this 
membrane, cells have to degrade the matrigel through secretion of ECM digesting enzymes. 
Since MDAMB231 is known to be among the most invasive breast cancer cell lines, this cell 
line was used for all invasion assays rather than using MCF7 cancer cells which tend to grow 
in colonies and are less invasive.  
 
3.6.1 hASC-derived myofibroblasts promote cancer cell 
invasion 
On the surface of a matrigel coated insert DiI-stained MDAMB231 cells were seeded either 
alone (35x103 cancer cells/well) or in co-culture with hASCs (70x103 hASCs/well) previously 
grown in regular medium, MDAMB231 conditioned medium (0%FBS, 24 h conditioning 
time) or regular medium containing 0.2ng/ml TGFβ1 for 4 days, respectively. Since 
MDAMB231 cancer cells grow faster than mesenchymal stem cells the cell ratio of 
MDAMB231 to hASCs was kept at 1:2 for all experiments. All cells were seeded in 600 µl of 
αMEM containing 5%FBS in the upper chamber of the filter insert. In order to create a 
serum gradient that would stimulate cell invasion the lower chamber was filled with αMEM 
containing 10%FBS. After 40 h of incubation all non-invaded cells were removed from the 
matrigel coated insert by scrubbing the top surface with cotton tip swabs and remaining 
cells on the lower side of the insert were additionally stained with the nuclear dye Hoechst 
33342 and analyzed under the microscope (representative images are shown in Fig. 3.14). 
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The remaining, invaded DiI + Hoechst 33342 positive cells were then counted under the 
microscope in five independent view fields at a 20x magnification. 
 
 
 
 
 
 
 
 
 
 
 
 
 
When counting the cancer cells that invaded into the matrigel after 40 hours, significantly 
more cancer cells invaded the coated membrane when co-seeded with hASCs (96.9 ± 23.2 
invaded cancer cells/view field) as compared to the mono-culture control group (33.6 ± 
14.9 invaded cancer cells/view field, Fig. 3.15). Furthermore, MDAMB231 cells became 
even more invasive when co-cultured with hASCs that had previously been cultured with 
either TCM (0%FBS, 24 h conditioning time) or 0.2 ng/ml TGFβ1 for 4 days (Figure 3.15). 
 
Figure 3.14  Representative images of DiI stained MDAMB231 cancer cells (red channel) that 
invaded into the matrigel after 40 h. The nuclei were counterstained with Hoechst (blue channel). 
Overlay of red with blue signal shows invaded cancer cells when seeded (a) alone or co-cultured 
with hASCs previously grown in (b) regular medium, (c) MDAMB231 tumor conditioned medium 
(TCM) or with (d) 0.2 ng/ml rTGFβ1 for 4 days, respectively. Scale bar, 50 μm. 
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To confirm these results invasion assays were partly repeated using GFP-labeled 
MDAMB231 cells. As shown in Figure 3.16 significantly more GFP-labeled MDAMB231 cells 
invaded the matrigel membrane when co-seeded with TCM-activated hASCs as compared 
to invaded GFP-MDAMB231 cells co-seeded with regular hASCs (104 ± 10.3 as compared to 
71 ± 5.6 cancer cells/view field). The invasion of GFP-MDAMB231 co-seeded with TCM-
activated hASCs was 1.46 times higher than that of GFP-MDAMB231 co-seeded with regular 
hASCs. Consequently these results confirm the previous experiments performed with DiI-
stained MDAMB231 cells, where the invasion was 1.7 times higher when comparing these 
two groups. 
 
Figure 3.15  TCM-activated hASCs and recombinant TGFβ1 treated hASCs promote tumor cell 
invasion. Invaded DiI+Hoechst33342-positive MDAMB231 cancer cells were counted in five 
independent view fields at 20x magnification in each group and are shown as mean ± SD with 
experiments being repeated three times. * indicates P<0.001. 
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3.6.2 Influence of hASC conditioned medium on breast cancer 
cell invasion 
To exclude that the observed increased invasion of breast cancer cells in co-culture with 
TCM-activated hASCs was merely an effect of higher cell density in the co-culture 
experiments and in order to assess the influence of conditioned medium from hASC-
derived myofibroblasts on the invasion of breast cancer cells, another series of invasion 
assays with MDAMB231 cells was performed. 
For this assay 35x103 cancer cells per well were seeded alone on the surface of the coated 
inserts and exposed to conditioned medium from hASCs, TGFβ1-treated hASCs, TCM-
Figure 3.16  Invasion assay with GFP-labeled MDAMB231. (A) Representative images of GFP-
labeled MDAMB231 cells that invaded into matrigel after 40 h. Green channel shows GFP-
MDAMB231 when seeded in co-culture with hASCs previously grown in (a) regular medium and 
(b) MDAMB231 tumor conditioned medium (TCM) for 4 days, respectively. Scale bar, 50 μm. (B) 
Invaded GFP-positive MDAMB231 cancer cells were counted in five independent view fields at 20x 
magnification in each group and are shown as mean ± SD with each experiment being repeated 
three times. * indicates P<0.0001. 
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activated hASCs and TCM-activated hASCs pre-incubated with 10 µM of the TGFβ1 receptor 
kinases inhibitor SB431542 for 30 minutes (see materials & methods 2.2.9 for details). After 
40h the assay was stopped, the top surface of the matrigel was scrubbed with cotton tip 
swabs and invaded cancer cells were stained with the nuclear dye Hoechst 33342. The 
remaining, invaded cells were counted in five independent view fields (see Fig. 3.17a-e for 
representative pictures of invaded MDAMB231).  
 
 
 
 
 
 
 
 
 
 
 
As shown in Figure 3.18, the invasion assay revealed that both CM from TCM-activated 
hASCs as well as CM from TGFβ1-treated hASCs significantly increased the invasion of 
MDAMB231 cancer cells as compared to CM from normal hASCs (74.2 ± 8.2 and 67.8 ± 10.5 
as compared to 46.2 ± 6.7 cancer cells/view field; P<0.005). Nevertheless CM from normal 
hASCs did already notably increase the invasion of MDAMB231 compared to cancer cells 
cultured with 5%FBS αMEM (control group). Moreover, the invasive capacity of cancer cells 
grown in CM from TCM-activated hASCs pretreated with the TGFβ1 receptor kinases 
Figure 3.17  Representative images of Hoechst33342 stained MDAMB231 cancer cells that 
invaded into matrigel after 40 h. The nuclei of the invaded cells were stained with Hoechst 33342 
(blue channel). Images show invaded cancer cells when cultured in (a) αMEM containing 5%FBS, 
(b) CM from hASCs, (c) CM from hASCs treated with 0.2 ng/ml rTGFβ1, (d) CM from TCM-activated 
hASCs and (e) CM from TCM-activated hASCs pretreated for 30 minutes with 10 µM SB431542 
(TGFβ1 receptor kinases inhibitor). Scale bar, 50 μm. 
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inhibitor SB431542 was considerably reduced when compared to the invasive rate of 
cancer cells grown in CM from TCM-activated cells for the same time (P<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Hence these results confirm the influence of conditioned medium from hASC-derived 
myofibroblasts on the invasion of breast cancer cells indicating that humoral factors 
secreted from TCM-activated or TGFβ1-treated hASCs must be involved in this process. 
Furthermore, the experiments demonstrate that inhibition of the TGFβ1 signaling pathway 
in hASCs reduces the potential of these cells to enhance the invasion of breast cancer cells 
in vitro. 
Figure 3.18  Conditioned medium from stimulated hASCs promotes tumor cell invasion. Hoechst 
33342-positive MDAMB231 cancer cells were counted in five independent view fields in each 
group and are shown as mean ± SD. Experiments were repeated three times. *P<0.001; ** 
P<0.005; *** P<0.0001. 
 
 
Discussion 
 
57 
4. Discussion 
 
The aim of the study was to assess whether human adipose tissue derived stem cells 
(hASCs) can develop into carcinoma-associated myofibroblasts under the influence of 
breast cancer cells in vitro. 
The tumor stroma and in particular stromal myofibroblasts play a crucial role in promoting 
many aspects of tumor development. However, the origin of these cells and the 
mechanisms by which they develop is still uncertain. Bone marrow derived mesenchymal 
stem cells (BMSCs) have recently been found to integrate into the tumor-associated stroma 
and to differentiate into myofibroblasts which act in a paracrine fashion on cancer cells to 
enhance their invasion (Spaeth et al., 2009). However, the potential of adjacent tissue 
resident stem cells from the fat tissue, which might represent early response cells within 
breast cancer, to differentiate into myofibroblasts and support breast cancer cell invasion 
had not been investigated so far. 
In this study it was shown that hASCs exhibit increased expression of the myofibroblast 
markers tenascin-C and α-SMA, when exposed to tumor cell conditioned medium from the 
two breast cancer cell lines MDAMB231 and MCF7. Further it was shown that tumor 
conditioned medium from MDAMB231 and MCF7 cells contains significant amounts of 
TGFβ1 and that the differentiation of hASCs towards myofibroblasts is dependent on TGFβ1 
signaling via Smad2 and Smad3 in hASCs. Additionally, hASCs secrete increased protein 
levels of SDF-1α and CCL5 when cultured in tumor cell conditioned medium (TCM) and 
TCM-activated hASCs promote the invasion of cancer cells in vitro. 
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4. 1 Myofibroblast phenotype in TCM-activated 
hASCs  
 
In a first set of experiments it was proven that the isolated human ASCs express 
mesenchymal stem cell markers. Using flow cytometric analysis it was shown that the cells 
are positive for CD surface markers CD29, CD44, CD90 and CD105 indicative of a broad 
differentiation potential. Cells are negative for CD34 and CD45 precluding contamination 
with hematopoietic cells. The expression profile of surface markers for hASCs as shown in 
these experiments is in line with previous reports from our (Bai et al., 2007a; Bai et al., 
2007b) and other groups (Schäffler and Büchler, 2007). 
For immunofluorescence experiments of myofibroblast-markers the focus was set on 
tenascin-C and α-SMA expression, since the relevance of both proteins as specifically 
important markers of carcinoma-associated myofibroblasts in reactive stroma of different 
types of cancer had been demonstrated in various studies. Tenascin-C, which 
physiologically modulates cell adhesion and migration and in cancer facilitates tumor cell 
invasion and metastasis, was found to be weakly expressed in normal tissue whereas both 
myofibroblasts in tumor stroma (Tuxhorn et al., 2002) as well as experimentally generated 
myofibroblasts (Kojima et al., 2010) showed strong staining. α-SMA expressing 
myofibroblasts are abundant in most invasive human breast cancers (Sappino et al., 1988) 
and many other epithelial carcinomas like that of the prostate, colon, lung and uterus 
(Orimo et al., 2001). In consequence it seemed of interest to focus on these markers in the 
context of the present study. 
Certainly there are many other markers for carcinoma-associated fibroblasts such as 
vimentin, fibroblast surface protein and fibroblast-activation protein (Orimo and Weinberg, 
2007) but as these markers have not been reported to be particularly specific for 
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carcinoma-associated myofibroblasts they were not used for the experiments performed in 
this study. 
Although the expression of myofibroblast markers in hASCs alone was very weak and breast 
cancer cells did not express any of these markers, increased expression levels of the typical 
myofibroblast protein α-SMA could be observed in co-cultures with either MDAMB231 or 
MCF7 breast cancer cells. Furthermore, hASCs did also acquire a myofibroblast phenotype 
(expression of α-SMA and tenascin-C) after exposure to TCM from MDAMB231 or MCF7, 
indicating that physical contact between the cells was not required and breast cancer cell 
derived humoral factors were sufficient for the differentiation. The differentiation of hASCs 
towards myofibroblast-like cells was time-dependent with the majority of cells expressing 
α-SMA after 4 days of culturing in TCM from either MDAMB231 or MCF7 as determined by 
immunofluorescence analysis. 
Similar experiments using bone marrow derived stem cells (BMSCs) and CM from various 
cancer cell lines were carried out by Mishra et al., who found that CM from breast cancer 
cells could induce α-SMA expression in BMSCs under defined tissue culture conditions 
(Mishra et al., 2008). Interestingly, in these experiments stimulation with TCM from 
MDAMB231 was performed for an entire period of 30 days after which most BMSCs 
expressed myofibroblast markers. In the experiments performed in this study the majority 
of hASCs did already differentiate into α-SMA positive cells after only 4 days of stimulation 
with MDAMB231 conditioned medium, showing that under defined tissue culture 
conditions  mesenchymal stem cells from the adipose tissue respond faster to TCM-
activation than those from the bone-marrow. It is therefore conceivable that also in in vivo 
breast cancer models, cells from the adipose tissue might respond faster to cancer signaling 
and be of special interest in the process of understanding the early cancer-stroma 
differentiation.  
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4. 2 Role of TGFβ in hASC-conversion towards 
myofibroblast-like cells 
 
TGFβ1 is considered to have a central role in inducing the myofibroblastic phenotype, 
because it is capable of up-regulating fibroblast α-SMA both in vitro and in vivo (Tuxhorn et 
al., 2001; Kojima et al., 2010). In many types of cancers, TGFβ1 is overexpressed by 
carcinoma cells (Teicher, 2001), and it has been proposed previously that the expression of 
this cytokine by prostate carcinoma cells induces reactive stroma (Webber et al., 1999). 
Moreover, bone marrow derived mesenchymal stem cells undergo myofibroblast 
differentiation, including increased production of α-SMA in response to TGFβ1 (Wang et al., 
2004).  
Both supernatants from MDAMB231 and MCF7 cancer cells contained significant amounts 
of TGFβ1 after 24 hours of culturing in serum free medium, whereas hASCs did not secrete 
any TGFβ1 as determined by ELISA. Additionally, IF staining revealed that hASCs express the 
TGFβ type II receptor. Upon binding of TGFβ1 this receptor can phosphorylate the type I 
receptor, activating the TGFβ-complex which eventually signals through the Smad pathway 
and elicits a broad range of gene responses (Massague, 2008). Western blot analysis 
confirmed that both hASCs cultured in MDAMB231 conditioned medium and hASCs 
stimulated with 0.2 ng/ml recombinant TGFβ1 (the same concentration of TGFβ1 as present 
in TCM from MDAMB231 as used for experiments) activate the Smad pathway in hASCs as 
demonstrated by high expression levels of p(hosphorylated)-Smad2, p-Smad3 and α-SMA. 
The up-regulation of p-Smad3 was quantified by western blot protein band density 
measurements and revealed over 20-fold higher induction of p-Smad3 in TCM-activated or 
rTGFβ1-stimulated hASCs as compared to control hASCs. Consequently the increased 
expression of α-SMA in hASCs in response to exposure to TCM appears to be influenced 
through TGFβ1 secretion by breast cancer cells in a paracrine fashion. 
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Jeon et al. showed that lysophosphatidic acid (LPA) which is enriched in ascites of ovarian 
cancer patients stimulates the production of TGFβ1 in hASCs (Jeon et al., 2008). Jeon 
further showed that TGFβ1 activates its receptor and stimulates the expression of α-SMA 
through an autocrine mechanism. In this present study it was confirmed that hASCs indeed 
express the TGFβ type II receptor, however, breast cancer cell derived TGFβ1 was 
responsible for the induction of the myofibroblast-like phenotype in a paracrine fashion 
and hASCs themselves did not produce TGFβ1. It is therefore conceivable that different 
types of cancer can use different mechanisms to induce the expression of α-SMA in cells of 
the surrounding stroma. 
After having identified TGFβ1 secreted from breast cancer cells as a potent agent in the 
differentiation of hASCs towards myofibroblasts, the question was raised if the observed 
effect could be inhibited by targeting TGFβ or its receptor on hASCs. Western blot analysis 
of hASCs cultured in TCM revealed that both, pretreatment of hASCs with 10 µM SB431542 
(a potent and selective inhibitor of TGFβ type I receptor kinases ALK4, ALK5 and ALK6 
(Inman et al., 2002)), as well as anti-TGFβ1 treatment with 0.2 µg/ml of a neutralizing 
antibody markedly reduced the phosphorylation of Smad2 and Smad3, and significantly 
reduced protein levels of α-SMA in hASCs. These findings were additionally verified by 
performing immunofluorescence analysis experiments, where it was shown that addition of 
either TGFβ1 neutralizing antibody or pretreatment of hASCs with SB431542 completely 
blocked the phenotypic switch of hASCs cultured in TCM towards α-SMA expressing 
myofibroblasts. It was confirmed that only specific inhibition and blocking of TGFβ was 
responsible for this effect using DMSO and normal chicken IgY as negative controls, 
respectively. It was also shown that exogenously added TGFβ1 dose-dependently increased 
the expression of α-SMA in hASCs. 
Considering these results, it would be very interesting to perform in vivo studies which 
explore the possibility to reduce the generation of tumor-promoting myofibroblasts in 
breast cancer through direct targeting and disrupting TGFβ signaling in ASCs. One difficulty 
of this approach could be the complex nature of TGFβ in cancer. While TGFβ acts as a 
tumor-suppressor in normal or premalignant cells it “switches sides” during cancer 
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progression and promotes tumor growth in a paracrine and/or autocrine manner 
(Massague, 2008). These contextual differences do also apply for the role of TGFβ within 
normal and tumor stroma. In normal stroma TGFβ has anti-tumorigenic effects and can 
suppress the expression of fibroblast-derived mitogenic factors that influence the adjacent 
epithelial cells. Bhowmick et al. generated mouse models in which the TGFβ RII gene was 
inactivated in fibroblasts of the prostate and forestomach which subsequently expressed 
elevated levels of mitogenic factors resulting in prostate and gastric carcinoma (Bhowmick 
et al., 2004). Hence, reducing the number of tumor-promoting myofibroblasts in cancer 
through inhibition of TGFβ signaling in stromal hASCs could involve other dangers which 
need to be taken into consideration. 
 
4. 3 Secretion of tumor-promoting factors from 
TCM-activated hASCs 
 
In a further step it was explored if myofibroblast-like cells derived from TCM-activated 
hASCs express tumor-promoting soluble factors. Carcinoma-associated myofibroblasts 
within tumor stroma have been shown to support cancer progression via the secretion of a 
huge variety of tumor-promoting chemokines. Out of these numerous tumor-promoting 
soluble factors the importance of SDF-1 and CCL5 in breast cancer had lately been 
demonstrated in various studies (Mishra et al., 2011; Karnoub et al., 2007; Orimo et al., 
2005). The secretion of SDF-1α and CCL5 was significantly increased in breast cancer TCM-
activated hASCs. 
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4.3.1 Stromal cell-derived factor 1  
Apart from its function in hematopoiesis and the development of the immune system the 
chemokine stromal cell-derived factor 1 (SDF-1), which signals primarily through its 
receptor CXCR4, plays a crucial role in the mobilization of metastatic cancer cells from 
various origins including cancer of the breast, ovary, kidney, lung, pancreas, colon and 
prostate (Sun et al., 2010), as well as for retention of acute leukemic cells in the bone 
marrow (Teicher and Fricker, 2010). This is achieved by promoting the migration of the 
CXCR4-expressing cancer cells towards a SDF-1 gradient produced by the stroma of these 
target organs (Burger and Kipps, 2006). Recent studies indicate that stromal cells in the 
primary tumor are an important source of SDF-1 (Mishra et al., 2011). The α-SMA protein 
which is present on myofibroblasts in tumor stroma is largely co-localized with the SDF-1 
protein, in contrast fibroblast-like cells positive for SDF-1 could not be detected in non-
cancer stroma in a study performed by Orimo et al. (Orimo et al., 2005). In a further study it 
was shown that LPA which is enriched in ascites of ovarian cancer patients stimulated the 
production of SDF-1 from human ASCs through a TGFβ1-Smad-dependent pathway (Jeon et 
al., 2008). 
For the detection of SDF-1α cell culture supernatants from hASCs were analyzed and it was 
shown that TCM-activation with both conditioned medium from MDAMB231 and MCF7 
significantly increased the secretion of SDF-1α reaching a maximum level after 72 h in 
culture. The increase in SDF-1α protein-level after 72h was 5.2-fold for hASCs cultured in 
MDAMB231 CM as compared to control hASCs. 
It was shown that murine ASCs can promote tumor growth in a SDF1/CXCR4 dependent 
manner (Muehlberg et al., 2009). In this model co-injection of murine ASCs with the murine 
breast cancer cell line 4T1 into nude male Balb/c mice caused tumors to grow significantly 
faster and knockdown of CXCR4 in 4T1 cells inhibited this effect. Moreover, murine ASCs 
that were isolated from the fat tissue surrounding the tumor, expressed significantly more 
SDF-1 than control ASCs. These results obtained in a murine breast cancer model in vivo are 
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in line with the data generated in vitro in this study and prove that both human and murine 
ASCs secrete elevated levels of SDF-1 when interacting with breast cancer cells. 
Furthermore these findings suggest that tumor cells produce specific factors that induce 
the production of SDF-1α by myofibroblasts. Since the present data demonstrated that 
TCM-derived TGFβ1 could generate myofibroblast-like cells from hASCs it was hypothesized 
that TGFβ1 was also responsible for the increased secretion of SDF-1α. Although inhibition 
of TGFβ1 receptor kinases with 10µM SB431542 significantly reduced the secretion of SDF-
1α in TCM-activated hASCs, direct stimulation of hASCs with 0.2 ng/ml rTGFβ1 for 72 h did 
not influence the secretion of SDF-1α. These data suggest that the TGFβ signaling pathway 
is involved in SDF-1α secretion from tumor-activated hASCs but not sufficient by itself to 
induce SDF-1α production and most likely a complex interplay between several factors is 
causing the secretion of SDF-1α.  
Contrary to the data of this present study, it was shown that myofibroblast-like cells, 
experimentally generated from fibroblasts using rTGFβ1, did show a 4-fold higher induction 
of SDF-1 in PCR analysis (Kojima et al., 2010). This differing data could be due to the fact 
that Kojima et al. performed cell-stimulation for 24 h using 10 ng/ml rTGFβ1, while in this 
study cells were stimulated over 72 h using only 0.2 ng/ml, which is a 50-fold lower 
concentration. 0.2 ng/ml rTGFβ1 is approximately the corresponding amount of TGF β1 
secreted by 8-10x106 MDAMB231 cells cultured for 24 h in 25 ml of medium. Since most 
experiments in this study were performed using TCM from 8-10x106 MDAMB231 cultured 
for 24 h in 25 ml of serum free medium, it seemed appropriate to use this concentration in 
order to best mimic the effect of TCM. 
Nevertheless, the present finding that inhibition of the TGFβ signaling pathway in TCM-
activated hASCs significantly reduced the secretion of tumor-promoting SDF-1α points out 
the essential role of TGFβ in the genesis of CAFs and indicates that targeting this cytokine in 
breast cancer could be of therapeutic interest. 
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4.3.2 CCL5 
BMSCs admixed with human breast cancer cells have been shown to produce high levels of 
the chemokine CCL5 which caused cancer cells to increase their migration, invasion and 
metastasis potential in vivo. The effects of CCL5 were dependent on mediation by its 
receptor CCR5 expressed on cancer cells and could be abolished by inhibition of CCR5 on 
cancer cells through small hairpin RNA (shRNA) knockdown (Karnoub et al., 2007). In that 
same study it was demonstrated that the induction of CCL5 required close physical contact 
between BMSCs and breast cancer cells. In a study performed by our group it was shown 
that CCL5 could also be produced in co-culture of hASCs with breast cancer cells, however 
physical contact between these cells was not required (Pinilla et al., 2009). While neither 
hASCs nor MDAMB231 secreted CCL5 when cultured alone, conditioned medium from 
MDAMB231 induced a “de novo” secretion of CCL5 from hASCs, suggesting that humoral 
factors present in TCM are responsible for CCL5-induction. In that study it was also shown 
that hASC-derived CCL5 was responsible for enhanced tumor cell invasion in vitro.  
In this present study experiments were conducted to find out more about the cellular 
sources of CCL5 in TCM-activated hASCs. For this reason hASCs were cultured in 
MDAMB231 conditioned medium, the cells were sorted for the expression of the 
myofibroblast marker tenascin-C using FACS and subsequently the secretion of CCL5 in 
tenascin-C negative and tenascin-C positive cell populations was determined. The results 
showed that CCL5 is mainly produced by tenascin-C positive cells. While tenascin-C negative 
cells do also secrete CCL5 to some extent, the secretion from tenascin-C positive cells is 3.4-
fold higher. Hence these data suggest that CCL5 is produced by tenascin-C positive 
myofibroblasts that developed from TCM-activated hASCs.  
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4.4 Breast cancer cell invasion in vitro 
 
90% of cancer deaths from solid tumors are being caused by metastasis which is preceded 
by local invasion (Gupta and Massague, 2006). A key feature of carcinoma-associated 
myofibroblasts is their ability to actively promote the invasion of cancer cells thereby 
paving the way for metastasis (De et al., 2008). In breast cancer these myofibroblasts show 
extensive gene expression changes in genes encoding invasion-associated factors and 
receptors (Allinen et al., 2004).  
Hence, it was investigated if experimentally generated, hASC-derived myofibroblasts do 
also resemble carcinoma-associated myofibroblasts in this regard. It had previously been 
demonstrated that hASCs promote cancer cell invasion through matrigel (a mixture of 
basement membrane proteins) in co-culture with breast cancer cells (Pinilla et al., 2009). 
These results were confirmed in the present study and it was further shown that breast 
cancer cell invasion in co-culture with hASCs was much more pronounced when hASCs had 
previously been stimulated with either TCM or recombinant TGFβ1 ( ~ 1.7 fold higher 
invasion of MDAMB231). These results were confirmed using both DiI-stained as well as 
GFP-labeled MDAMB231 cancer cells and indicate that hASC-derived myofibroblasts are 
responsible for enhanced invasion.  
Additionally conditioned medium from hASC-derived myofibroblasts alone already 
significantly increased the invasion of MDAMB231 as compared to CM from normal hASCs. 
This invasion promoting effect could be abolished by inhibition of the TGFβ1 signaling 
pathway in hASCs, indicating that TGFβ was an indirect proinvasive factor for MDAMB231 
cancer cells as it converts hASCs into myofibroblast-like cells that strongly stimulate 
invasion. These results do also indicate that cancer invasion can be promoted indirectly by 
the release of tumor-induced host factors from hASC-derived myofibroblasts and CCL5  had  
been identified as one possible factor in a previous study (Pinilla et al., 2009). 
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These findings support the results of previously performed in vitro studies which 
demonstrate that cancer-cell derived TGFβ can sustain the production of pro-invasive 
factors from myofibroblasts in various types of cancer (Lewis et al., 2003; Casey et al., 2008; 
De et al., 2004).  
Together with the findings that TCM-activated hASCs express myofibroblast-like 
immunocytochemical markers, these results further corroborate the assumption that hASCs 
differentiate into functional carcinoma-associated myofibroblasts and prove the essential 
role of carcinoma-derived TGFβ1 in the interactions between breast cancer cells and 
mesenchymal stem cells from adipose tissue. 
 
4.5 Conclusion and perspective 
 
The essential feature of the present study, which was designed to reproduce the 
interactions of epithelial breast cancer cells with adipose tissue derived mesenchymal stem 
cells in vitro, is that under the influence of tumor cell conditioned medium, hASCs can 
differentiate into myofibroblasts. The differentiation of hASCs towards myofibroblasts 
expressing α-SMA and tenascin-C is dependent on TGFβ1 secreted from breast cancer cells 
and can be abolished using a neutralizing antibody to TGFβ1 as well as by pretreatment of 
hASCs with SB431542, a selective TGFβ1 receptor kinases inhibitor. More importantly, 
these hASC-derived myofibroblasts exhibit functional properties of carcinoma-associated 
myofibroblasts including the ability to produce the tumor-promoting chemokines SDF-1α 
and CCL5 and support tumor cell invasion as shown by an in vitro invasion assay. Together, 
these findings are of special interest, since human mesenchymal stem cells derived from 
adipose tissue are particularly abundant in breast tissue and might therefore be the most 
potent early response cells during cancer expansion. 
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The treatment of metastatic breast cancer remains extremely challenging and 
unsatisfactory. The problem might be that for many years the main approach in treating 
cancer was trying to target and kill only proliferating cancer cells. However cancer cells 
regularly acquire therapeutic resistance presumably because of their innate genomic 
instability (Martin et al., 2010; Casey et al., 2008) and the existence of dormant, drug 
resistant cells that persist for many months can lead to metastatic relapse and death 
despite aggressive chemotherapy (FEHM et al., 2008). Lately the importance of the 
microenvironment´s role in cancer has been widely recognized. With the use of new drugs 
in metastatic breast cancer such as bevacizumab, a monoclonal antibody against vascular 
endothelial growth factor (VEGF), which among many other factors is important in the 
development of reactive stroma (Brown et al., 1999), attempts are being made towards 
targeting the cancer microenvironment. Several clinical trials have reported that with the 
use of bevacizumab significant improvements in progression-free survival of patients with 
metastatic breast cancer can be achieved (Hamilton and Blackwell, 2011). In order to 
further improve the treatment of this deadly cancer, additional pharmacological 
approaches targeting stromal cells need to be taken. 
The present findings identify TGFβ1 secreted from breast cancer cells as a key factor in the 
differentiation of tissue resident stem cells towards myofibroblasts and suggest that 
inhibition of the associated TGFβ1 signaling pathway in hASCs can offer a way to prevent 
the formation of these tumor-promoting cells in vitro. It would now be necessary and 
interesting to investigate if the effects of TGFβ inhibition in hASCs in vitro can also be 
observed in an in vivo mouse model. As mentioned above, the potential danger of this 
approach, such as carcinoma-formation itself (Bhowmick et al., 2004), needs to be 
considered and critically investigated when following this approach. 
Future in vitro and in vivo studies on adipose tissue derived stem cells within the breast 
cancer microenvironment under special consideration of TGFβ1 could offer a very 
promising tool to further study the progression of hASCs towards myofibroblasts and 
eventually pave the way for the development of more efficient therapeutic strategies 
against breast cancer. 
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5. Summary 
 
Major advances in understanding and treating breast cancer have been made in the last 
two decades, yet it remains a significant problem with breast cancer being the most 
commonly identified cancer and the leading cause of cancer death among women 
worldwide. For many years breast cancer research has mainly focused on genetically 
changed cancer cells. However, recently the importance of the stromal compartment 
surrounding cancer cells in facilitating tumor growth, invasion and metastasis has been 
widely recognized. Cumulating evidence suggests that in particular carcinoma-associated 
myofibroblasts play a key role within the tumor stroma and influence many aspects of 
carcinogenesis. Nevertheless, the cell type of origin as well as the precise mechanisms by 
which these cells develop has not been conclusively established and remains controversial. 
The role of human adipose tissue derived stem cells (hASCs) in this context has not been 
studied so far. hASCs are locally adjacent to epithelial breast cancer cells and might 
represent early response cells within the tumor stroma. Hence, the aim of this study was to 
investigate whether carcinoma-associated myofibroblasts may originate from hASCs.  
The present study revealed that a significant percentage of hASCs differentiate into 
myofibroblast-like cells expressing alpha smooth muscle actin (α-SMA) and tenascin-C when 
exposed to conditioned medium from the human epithelial breast cancer cell lines 
MDMAB231 and MCF7. This process is induced by transforming growth factor beta 1 
(TGFβ1) secreted from breast cancer cells. It was shown that conditioned medium from 
MDMAB231 and MCF7 contains significant amounts of TGFβ1. It could further be 
demonstrated that the differentiation of hASCs towards myofibroblasts is dependent on 
TGFβ1 signaling via phosphorylation of Smad2 and Smad3 in hASCs. The induction of 
myofibroblasts can be abolished using a neutralizing antibody to TGFβ1 as well as by 
pretreatment of hASCs with SB431542, a selective inhibitor of the TGFβ1 activin receptor-
like kinases 4, 5 and 7. Additionally, hASC-derived myofibroblasts exhibit functional 
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properties of carcinoma-associated myofibroblasts such as the increased secretion of the 
tumor-promoting soluble factors SDF-1α and CCL5. Furthermore hASC-derived 
myofibroblasts as well as conditioned medium from these cells promote the in vitro 
invasion of MDAMB231 breast cancer cells. Moreover inhibition of the TGFβ1 signaling 
pathway in hASCs reduces the potential of these cells to enhance the invasion of breast 
cancer cells. 
Overall, the data of the present study suggest that human adipose tissue derived stem cells 
can differentiate into carcinoma-associated myofibroblast under the influence of TGFβ1 
secreted from breast cancer cells in vitro. The differentiation of hASCs towards these 
tumor-promoting cells can be abolished by targeting the TGFβ1 signaling pathway. Hence, 
inhibition of the TGFβ1 signaling pathway may prove to be an interesting target for breast 
cancer therapies. In vivo studies on the cancer microenvironment under special 
consideration of the interactions between hASCs and cancer cells should be of interest for 
breast cancer research in the future. 
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6. Zusammenfassung 
 
In den letzten Jahrzehnten konnten bedeutende Forstschritte bezüglich des Verständnisses 
und der Behandlung von Brustkrebs erzielt werden. Dennoch stellt Brustkrebs bei Frauen 
die weltweit am häufigsten diagnostizierte Krebserkrankung dar und ist auch die häufigste 
Krebstodesursache bei Frauen. Über viele Jahre hinweg konzentrierte sich die 
Brustkrebsforschung hauptsächlich auf die Untersuchung genetisch veränderter 
Krebszellen. Allerdings hat sich gerade in den letzten Jahren gezeigt, dass das den Tumor 
umgebende Stroma eine wesentliche Rolle für die Tumorprogression spielt und sowohl das 
Tumorwachstum im Ursprungsgewebe als auch die Tumorzellinvasion in das umgebende 
Gewebe sowie die Metastasenbildung erheblich erleichtert. Innerhalb des Tumorstromas 
spielen insbesondere tumor-assoziierte Myofibroblasten eine Schlüsselrolle und 
beeinflussen zahlreiche Aspekte der Kanzerogenese.  Dennoch ist es bisher weder 
hinreichend gelungen den Ursprung dieser Zellen, noch die genauen molekularen 
Mechanismen durch welche diese Zellen sich entwickeln, zu identifizieren.  Die Rolle von 
humanen mesenchymalen Stammzellen des Fettgewebes (human adipose tissue derived 
stem cells [hASCs]) wurde in diesem Zusammenhang bisher nicht untersucht. Innerhalb des 
Tumorstromas befinden sich hASCs in nächster Nähe zu Brustkrebszellen und können somit 
frühzeitig durch diese beeinflusst werden. Das Ziel der vorliegenden Studie war es daher zu 
untersuchen, ob sich tumor-assoziierte Myofibroblasten von humanen mesenchymalen 
Stammzellen des Fettgewebes ableiten können.   
In der vorliegenden Studie konnte gezeigt werden, dass eine signifikante Anzahl von hASCs 
unter dem Einfluss von konditioniertem Medium der humanen Mammakarzinom-Zelllinien 
MDAMB231 und MCF7 zu Myofibroblasten differenzieren, die alpha smooth muscle actin 
(α-SMA) und tenascin-C exprimieren. Dieser Prozess wird durch das von MDAMB231 und 
MCF7 Krebszellen sezernierte TGFβ1 (transforming growth factor beta 1) induziert. Es 
wurde demonstriert, dass die Differenzierung mittels der Phosphorylierung von Smad2 und 
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Smad3 im Rahmen der TGFβ1-Signalübertragung in hASCs abläuft. Die Entstehung von 
Myofibroblasten konnte durch den Einsatz eines neutralisierenden Antikörpers sowie durch 
die Vorbehandlung von hASCs mit SB431542, einem selektiven Inhibitor der TGFβ1 Aktivin-
Rezeptor-like-Kinasen 4, 5 und 7, unterbunden werden. Zusätzlich konnte gezeigt werden, 
dass von mesenchymalen Stammzellen abstammende Myofibroblasten funktionelle 
Eigenschaften tumor-assoziierter Myofibroblasten aufweisen, unter anderem die 
vermehrte Sekretion der Chemokine SDF-1α und CCL5, welche die Tumorprogression 
vorantreiben.  Weiterhin fördern die experimentell generierten Myofibroblasten sowie 
konditioniertes Medium dieser  Zellen die Invasion von MDAMB231 Brustkrebszellen in 
vitro. Die beobachtete, verstärkte Invasivität  der Brustkrebszellen konnte durch die 
Hemmung der TGFβ1-Singalübertragung in mesenchymalen Stammzellen mittels   
SB431542 signifikant vermindert werden.   
Zusammenfassend konnte gezeigt werden, dass humane mesenchymale Stammzellen des 
Fettgewebes (hASCs) in Interaktion mit Brustkrebszellen unter dem Einfluss von TGFβ1, zu 
tumor-assoziierten Myofibroblasten differenzieren können. Die Differenzierung von hASCs 
zu Myofibroblasten, welche wesentlich zur Tumorprogression beitragen, kann mittels der 
Hemmung des TGFβ1-Signalweges verhindert werden. Demnach könnte die Hemmung des  
TGFβ1-Signalweges im Tumorstroma eine interessante Option für zukünftige 
Brustkrebstherapieformen darstellen, indem dadurch die Homöostase der Tumoren gestört 
würde.  Weiterführende in vivo Studien zum Tumorumfeld, die im Besonderen die 
Interaktionen von hASCs mit Brustkrebszellen untersuchen,  könnten somit für die 
Brustkrebsforschung zukünftig von Bedeutung sein.   
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7. Index of abbreviations 
 
αMEM   Alpha-modification of Eagle´s medium 
α-SMA   Alpha smooth muscle actin 
AB   Antibody 
ALK   Activin receptor-like kinase 
ASC   Adipose tissue derived stem cell 
BMSC   Bone marrow derived stem cell 
BRCA1/2  Breast cancer 1/2 
BSA   Bovine serum albumin 
CAF   Carcinoma-associated (myo)fibroblast 
CCL5   Chemokine (C-C motif) ligand 5 
CD   Cluster of differentiation 
CM   Conditioned medium 
CXCR4   C-X-C chemokine receptor 4 
DiI   1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate 
DMSO   Dimethylsulfoxide 
ECM   Extracellular matrix 
EDTA   Ethylenediaminetetraacetic acid  
ELISA   Enzyme-linked immunosorbent assay 
EMT   Epithelial to mesenchymal transition 
EndMT   Endothelial to mesenchymal transition 
ER   Estrogen  
FACS   Fluorescence-activated cell sorting 
FBS   Fetal bovine serum 
Fig   Figure 
GFP   Green fluorescent protein 
h   Human 
Index of Abbreviations 
 
74 
HBSS   Hank´s balanced salt solution 
HCl   Hydrochloric acid 
HER2   Human epidermal growth factor receptor 2 
IF   Immunofluorescence 
LPA   Lysophosphatidic acid  
MCF7   Human breast cancer cell line MCF7 
MDAMB231  Human breast cancer cell line MDAMB231 
PBS   Phosphate-buffered saline 
PD   Population doubling 
PE   Phyocoerythrin 
PerCP   Peridinin-chlorophyll 
PR   Progesterone  
p-Smad2/3  Phosphorylated Smad2/3 
r   Recombinant 
rpm   Revolutions per minute 
RT   Room temperature 
SD   Standard deviation 
SDF-1α   Stromal cell-derived factor 1 alpha 
SDS   Sodium dodecyl sulfate 
Smad2/3  Mothers against decapentaplegic homolog 2/3 
TBS   Tris buffered saline 
TBST   Tris buffered saline with Tween® 20 
TCM   Tumor conditioned medium 
TGFβ RI/II  Transforming growth factor beta type I/II receptor 
TGFβ   Transforming growth factor beta 
Tris   Tris(hydroxymethyl)aminomethane 
VEGF   Vascular endothelial growth factor 
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8. Index of figures 
 
Figure 2.1: Human adipose tissue derived stem cells in culture 
Figure 2.2: Breast cancer cell lines MDAMB231/MCF7 in co-culture with hASCs 
Figure 3.1: hASCs express CD surface markers typical for mesenchymal stem cells 
Figure 3.2: Direct co-culture of hASCs with breast cancer cells 
Figure 3.3: IF staining of hASCs for myofibroblast markers 
Figure 3.4: Quantitative analysis of the expression of α-SMA in hASCs cultured for 1 or 
4 days in TCM or serum-free medium 
Figure 3.5: Tumor conditioned medium contains TGFβ1 
Figure 3.6: IF staining of hASCs with a fluorescein conjugated anti-TGFβ RII antibody 
Figure 3.7: Induction of p-Smad3 in stimulated hASCs 
Figure 3.8: Inhibition of Samd2/3 phosphorylation and α-SMA expression 
Figure 3.9: TGFβ1 is critical to hASC-differentiation towards myofibroblast-like cells 
Figure 3.10: TCM stimulates the secretion of SDF-1α from hASCs 
Figure 3.11: Effect of TGFβ1 on SDF-1α in hASCs 
Figure 3.12: FACS sorting analysis of hASCs for tenascin-C 
Figure 3.13: Tenascin-C positive hASC-derived myofibroblasts produce elevated levels of 
CCL5 
Figure 3.14: Representative images of DiI stained MDAMB231 cancer cells that invaded 
into matrigel after 40 h 
Figure 3.15: TCM-activated hASCs and rTGFβ1 treated hASCs promote tumor cell 
invasion 
Figure 3.16: Invasion assay with GFP-labeled MDAMB231 
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Figure 3.17: Representative images of Hoechst33342 stained MDAMB231 cancer cells 
that invaded the matrigel after 40 h 
Figure 3.18: Conditioned medium from stimulated hASCs promotes tumor cell invasion 
 
References 
 
77 
9. References 
Reference List 
 
 1.  Allinen,M., Beroukhim,R., Cai,L., Brennan,C., Lahti-Domenici,J., Huang,H., Porter,D., 
Hu,M., Chin,L., Richardson,A., Schnitt,S., Sellers,W.R., and Polyak,K. (2004). 
Molecular characterization of the tumor microenvironment in breast cancer. 
Cancer Cell 6, 17-32. 
 2.  Angeli,F., Koumakis,G., Chen,M.C., Kumar,S., and Delinassios,J.G. (2009). Role of 
Stromal Fibroblasts in Cancer: Promoting or Impeding? Tumor Biology 30, 109-120. 
 3.  Bai,X., Ma,J., Pan,Z., Song,Y.H., Freyberg,S., Yan,Y., Vykoukal,D., and Alt,E. (2007a). 
Electrophysiological properties of human adipose tissue-derived stem cells. Am. J. 
Physiol Cell Physiol 293, C1539-C1550. 
 4.  Bai,X., Sadat,S., Gehmert,S., Alt,E., and Song,Y.H. (2007b). VEGF receptor Flk-1 plays 
an important role in c-kit expression in adipose tissue derived stem cells. FEBS Lett. 
581, 4681-4684. 
 5.  Bhowmick,N.A., Chytil,A., Plieth,D., Gorska,A.E., Dumont,N., Shappell,S., 
Washington,M.K., Neilson,E.G., and Moses,H.L. (2004). TGF-beta Signaling in 
Fibroblasts Modulates the Oncogenic Potential of Adjacent Epithelia. Science 303, 
848-851. 
 6.  Bierie,B. and Moses,H.L. (2006). Tumour microenvironment: TGF[beta]: the 
molecular Jekyll and Hyde of cancer. Nat Rev Cancer 6, 506-520. 
 7.  Brown,L.F., Guidi,A.J., Schnitt,S.J., Van De Water,L., Iruela-Arispe,M.L., Yeo,T.K., 
Tognazzi,K., and Dvorak,H.F. (1999). Vascular Stroma Formation in Carcinoma in 
Situ, Invasive Carcinoma, and Metastatic Carcinoma of the Breast. Clinical Cancer 
Research 5, 1041-1056. 
 8.  Burger,J.A. and Kipps,T.J. (2006). CXCR4: a key receptor in the crosstalk between 
tumor cells and their microenvironment. Blood 107, 1761-1767. 
 9.  Casey,T., Eneman,J., Crocker,A., White,J., Tessitore,J., Stanley,M., Harlow,S., 
Bunn,J., Weaver,D., Muss,H., and Plaut,K. (2008). Cancer associated fibroblasts 
stimulated by transforming growth factor ß1 increase invasion rate of tumor cells: a 
population study. Breast Cancer Research and Treatment 110, 39-49. 
References 
 
78 
 10.  Chia,S.K., Speers,C.H., D'yachkova,Y., Kang,A., Malfair-Taylor,S., Barnett,J., 
Coldman,A., Gelmon,K.A., O'Reilly,S.E., and Olivotto,I.A. (2007). The impact of new 
chemotherapeutic and agents on survival in a population-based of women with 
metastatic breast cancer hormone cohort. Cancer 110, 973-979. 
 11.  De,W.O., Demetter,P., Mareel,M., and Bracke,M. (2008). Stromal myofibroblasts 
are drivers of invasive cancer growth. Int. J. Cancer 123, 2229-2238. 
 12.  De,W.O., Nguyen,Q.D., Van,H.L., Bracke,M., Bruyneel,E., Gespach,C., and Mareel,M. 
(2004). Tenascin-C and SF/HGF produced by myofibroblasts in vitro provide 
convergent pro-invasive signals to human colon cancer cells through RhoA and Rac. 
FASEB J. 18, 1016-1018. 
 13.  Derynck,R. and Akhurst,R.J. (2007). Differentiation plasticity regulated by TGF-
[beta] family proteins in development and disease. Nat Cell Biol 9, 1000-1004. 
 14.  DeSantis,C., Siegel,R., Bandi,P., and Jemal,A. (2011). Breast cancer statistics, 2011. 
Ca-A Cancer Journal for Clinicians 61, 409-418. 
 15.  Desruisseau,S., Palmari,J., Giusti,C., Romain,S., Martin,P.M., and Berthois,Y. (2006). 
Determination of TGF[beta]1 protein level in human primary breast cancers and its 
relationship with survival. Br J Cancer 94, 239-246. 
 16.  Direkze,N.C., Hodivala-Dilke,K., Jeffery,R., Hunt,T., Poulsom,R., Oukrif,D., 
Alison,M.R., and Wright,N.A. (2004). Bone marrow contribution to tumor-
associated myofibroblasts and fibroblasts. Cancer Res. 64, 8492-8495. 
 17.  Dvorak,H.F. (1986). Tumors: Wounds That Do Not Heal. N Engl J Med 315, 1650-
1659. 
 18.  FEHM,T., MUELLER,V., MARCHES,R., KLEIN,G., GUECKEL,B., NEUBAUER,H., 
SOLOMAYER,E., and BECKER,S. (2008). Tumor cell dormancy: implications for the 
biology and treatment of breast cancer. APMIS 116, 742-753. 
 19.  Gennari,A., Conte,P., Rosso,R., Orlandini,C.A., and Bruzzi,P. (2005). Survival of 
metastatic breast carcinoma patients over a 20-year period - A retrospective 
analysis based on individual patient data from six consecutive studies. Cancer 104, 
1742-1750. 
 20.  Gimble,J.M., Katz,A.J., and Bunnell,B.A. (2007). Adipose-derived stem cells for 
regenerative medicine. Circ. Res. 100, 1249-1260. 
 21.  Giordano,S.H. (2003). Update on Locally Advanced Breast Cancer. The Oncologist 8, 
521-530. 
References 
 
79 
 22.  Grinnell,F. (1994). Fibroblasts, Myofibroblasts, and Wound Contraction. Journal of 
Cell Biology 124, 401-404. 
 23.  Gupta,G.P. and Massague,J. (2006). Cancer Metastasis: Building a Framework. Cell 
127, 679-695. 
 24.  Hamilton,E.P. and Blackwell,K.L. (2011). Safety of Bevacizumab in Patients with 
Metastatic Breast Cancer. Oncology 80, 314-325. 
 25.  Haviv,I., Polyak,K., Qiu,W., Hu,M., and Campbell,I. (2009). Origin of carcinoma 
associated fibroblasts. Cell Cycle 8, 589-595. 
 26.  Hayes, D. F. An overview of breast cancer from online database "Up to date".  2011.  
Ref Type: Internet Communication 
 27.  Hsia,H.C. and Schwarzbauer,J.E. (2005). Meet the Tenascins: Multifunctional and 
Mysterious. Journal of Biological Chemistry 280, 26641-26644. 
 28.  Hu,B., Wu,Z., and Phan,S.H. (2003). Smad3 mediates transforming growth factor-
beta-induced alpha-smooth muscle actin expression. Am. J. Respir. Cell Mol. Biol. 
29, 397-404. 
 29.  Hulka,B.S. and Moorman,P.G. (2008). Breast cancer: hormones and other risk 
factors (Reprinted from Maturitas, vol 38, pg 103-113). Maturitas 61, 203-213. 
 30.  Inman,G.J., Nicolás,F.J., Callahan,J.F., Harling,J.D., Gaster,L.M., Reith,A.D., 
Laping,N.J., and Hill,C.S. (2002). SB-431542 Is a Potent and Specific Inhibitor of 
Transforming Growth Factor ß Superfamily Type I Activin Receptor-Like Kinase (ALK) 
Receptors ALK4, ALK5, and ALK7. Molecular Pharmacology 62, 65-74. 
 31.  Ishii,G., Sangai,T., Oda,T., Aoyagi,Y., Hasebe,T., Kanomata,N., Endoh,Y., Okumura,C., 
Okuhara,Y., Magae,J., Emura,M., Ochiya,T., and Ochiai,A. (2003). Bone-marrow-
derived myofibroblasts contribute to the cancer-induced stromal reaction. 
Biochem. Biophys. Res. Commun. 309, 232-240. 
 32.  Jemal,A. (2011). Global Cancer Statistics (vol 61, pg 69, 2011). Ca-A Cancer Journal 
for Clinicians 61, 134. 
 33.  Jeon,E.S., Moon,H.J., Lee,M.J., Song,H.Y., Kim,Y.M., Cho,M., Suh,D.S., Yoon,M.S., 
Chang,C.L., Jung,J.S., and Kim,J.H. (2008). Cancer-derived lysophosphatidic acid 
stimulates differentiation of human mesenchymal stem cells to myofibroblast-like 
cells. Stem Cells 26, 789-797. 
 34.  Kalluri,R. and Zeisberg,M. (2006). Fibroblasts in cancer. Nat Rev Cancer 6, 392-401. 
References 
 
80 
 35.  Karnoub,A.E., Dash,A.B., Vo,A.P., Sullivan,A., Brooks,M.W., Bell,G.W., 
Richardson,A.L., Polyak,K., Tubo,R., and Weinberg,R.A. (2007). Mesenchymal stem 
cells within tumour stroma promote breast cancer metastasis. Nature 449, 557-
563. 
 36.  Kojima,Y., Acar,A., Eaton,E.N., Mellody,K.T., Scheel,C., Ben-Porath,I., Onder,T.T., 
Wang,Z.C., Richardson,A.L., Weinberg,R.A., and Orimo,A. (2010). Autocrine TGF-
beta and stromal cell-derived factor-1 (SDF-1) signaling drives the evolution of 
tumor-promoting mammary stromal myofibroblasts. Proceedings of the National 
Academy of Sciences of the United States of America 107, 20009-20014. 
 37.  Kunz-Schughart,L.A. and Knuechel,R. (2002). Tumor-associated fibroblasts (part I): 
Active stromal participants in tumor development and progression? Histol. 
Histopathol. 17, 599-621. 
 38.  Lewis,M.P., Lygoe,K.A., Nystrom,M.L., Anderson,W.P., Speight,P.M., Marshall,J.F., 
and Thomas,G.J. (2003). Tumour-derived TGF-[beta]1 modulates myofibroblast 
differentiation and promotes HGF//SF-dependent invasion of squamous carcinoma 
cells. Br J Cancer 90, 822-832. 
 39.  Liotta,L.A. and Kohn,E.C. (2001). The microenvironment of the tumour-host 
interface. Nature 411, 375-379. 
 40.  Martin,S.A., Hewish,M., Lord,C.J., and Ashworth,A. (2010). Genomic instability and 
the selection of treatments for cancer. Journal of Pathology 220, 281-289. 
 41.  Massague,J. (2008). TGFbeta in Cancer. Cell 134, 215-230. 
 42.  Mishra,P.J., Mishra,P.J., Humeniuk,R., Medina,D.J., Alexe,G., Mesirov,J.P., 
Ganesan,S., Glod,J.W., and Banerjee,D. (2008). Carcinoma-associated fibroblast-like 
differentiation of human mesenchymal stem cells. Cancer Res. 68, 4331-4339. 
 43.  Mishra,P., Banerjee,D., and Ben-Baruch,A. (2011). Chemokines at the crossroads of 
tumor-fibroblast interactions that promote malignancy. Journal of Leukocyte 
Biology 89, 31-39. 
 44.  Muehlberg,F.L., Song,Y.H., Krohn,A., Pinilla,S.P., Droll,L.H., Leng,X., 
Seidensticker,M., Ricke,J., Altman,A.M., Devarajan,E., Liu,W., Arlinghaus,R.B., and 
Alt,E.U. (2009). Tissue-resident stem cells promote breast cancer growth and 
metastasis. Carcinogenesis 30, 589-597. 
 45.  Mueller,L., Goumas,F.A., Affeldt,M., Sandtner,S., Gehling,U.M., Brilloff,S., Walter,J., 
Karnatz,N., Lamszus,K., Rogiers,X., and Broering,D.C. (2007). Stromal Fibroblasts in 
Colorectal Liver Metastases Originate From Resident Fibroblasts and Generate an 
References 
 
81 
Inflammatory Microenvironment. The American Journal of Pathology 171, 1608-
1618. 
 46.  Muller,A., Homey,B., Soto,H., Ge,N., Catron,D., Buchanan,M.E., McClanahan,T., 
Murphy,E., Yuan,W., Wagner,S.N., Barrera,J.L., Mohar,A., Verastegui,E., and 
Zlotnik,A. (2001). Involvement of chemokine receptors in breast cancer metastasis. 
Nature 410, 50-56. 
 47.  O'Connell,J.T., Sugimoto,H., Cooke,V.G., MacDonald,B.A., Mehta,A.I., LeBleu,V.S., 
Dewar,R., Rocha,R.M., Brentani,R.R., Resnick,M.B., Neilson,E.G., Zeisberg,M., and 
Kalluri,R. (2011). VEGF-A and Tenascin-C produced by S100A4+ stromal cells are 
important for metastatic colonization. Proceedings of the National Academy of 
Sciences 108, 16002-16007. 
 48.  Orimo,A., Gupta,P.B., Sgroi,D.C., renzana-Seisdedos,F., Delaunay,T., Naeem,R., 
Carey,V.J., Richardson,A.L., and Weinberg,R.A. (2005). Stromal fibroblasts present 
in invasive human breast carcinomas promote tumor growth and angiogenesis 
through elevated SDF-1/CXCL12 secretion. Cell 121, 335-348. 
 49.  Orimo,A., Tomioka,Y., Shimizu,Y., Sato,M., Oigawa,S., Kamata,K., Nogi,Y., Inoue,S., 
Takahashi,M., Hata,T., and Muramatsu,M. (2001). Cancer-associated 
Myofibroblasts Possess Various Factors to Promote Endometrial Tumor 
Progression. Clinical Cancer Research 7, 3097-3105. 
 50.  Orimo,A. and Weinberg,R.A. (2007). Heterogeneity of stromal fibroblasts in tumor. 
Cancer Biology & Therapy 6, 618-619. 
 51.  Ostman,A. and Augsten,M. (2009). Cancer-associated fibroblasts and tumor 
growth--bystanders turning into key players. Curr. Opin. Genet. Dev. 19, 67-73. 
 52.  Paget,S. (1889). The distribution of secondary growths in cancer of the breast. The 
Lancet 133, 571-573. 
 53.  Perou,C.M., Sorlie,T., Eisen,M.B., van de Rijn,M., Jeffrey,S.S., Rees,C.A., Pollack,J.R., 
Ross,D.T., Johnsen,H., Akslen,L.A., Fluge,O., Pergamenschikov,A., Williams,C., 
Zhu,S.X., Lonning,P.E., Borresen-Dale,A.L., Brown,P.O., and Botstein,D. (2000). 
Molecular portraits of human breast tumours. Nature 406, 747-752. 
 54.  Pinilla,S., Alt,E., bdul Khalek,F.J., Jotzu,C., Muehlberg,F., Beckmann,C., and 
Song,Y.H. (2009). Tissue resident stem cells produce CCL5 under the influence of 
cancer cells and thereby promote breast cancer cell invasion. Cancer Letters 284, 
80-85. 
 55.  Quante,M., Tu,S.P., Tomita,H., Gonda,T., Wang,S.S.W., Takashi,S., Baik,G.H., 
Shibata,W., DiPrete,B., Betz,K.S., Friedman,R., Varro,A., Tycko,B., and Wang,T.C. 
References 
 
82 
(2011). Bone Marrow-Derived Myofibroblasts Contribute to the Mesenchymal Stem 
Cell Niche and Promote Tumor Growth. Cancer Cell 19, 257-272. 
 56.  Radisky,D.C., Kenny,P.A., and Bissell,M.J. (2007). Fibrosis and cancer: Do 
myofibroblasts come also from epithelial cells via EMT? J. Cell. Biochem. 101, 830-
839. 
 57.  Ronnov-Jessen,L. and Petersen,O.W. (1993). Induction of alpha-smooth muscle 
actin by transforming growth factor-beta 1 in quiescent human breast gland 
fibroblasts. Implications for myofibroblast generation in breast neoplasia. Lab 
Invest 68, 696-707. 
 58.  RonnovJessen,L. and Petersen,O.W. (1996). A function for filamentous alpha-
smooth muscle actin: Retardation of motility in fibroblasts. Journal of Cell Biology 
134, 67-80. 
 59.  Sappino,A.P., Skalli,O., Jackson,B., Schurch,W., and Gabbiani,G. (1988). Smooth-
muscle differentiation in stromal cells of malignant and non-malignant breast 
tissues. Int. J. Cancer 41, 707-712. 
 60.  Schafer,M. and Werner,S. (2008). Cancer as an overhealing wound: an old 
hypothesis revisited. Nat Rev Mol Cell Biol 9, 628-638. 
 61.  Schäffler,A. and Büchler,C. (2007). Concise Review: Adipose Tissue-Derived Stromal 
CellsBasic and Clinical Implications for Novel Cell-Based Therapies. Stem Cells 25, 
818-827. 
 62.  Shackney,S.E. and Silverman,J.F. (2003). Molecular evolutionary patterns in breast 
cancer. Advances in Anatomic Pathology 10, 278-290. 
 63.  Sheen-Chen,S.M., Chen,H.S., Sheen,C.W., Eng,H.L., and Chen,W.J. (2001). Serum 
Levels of Transforming Growth Factor {beta}1 in Patients With Breast Cancer. Arch 
Surg 136, 937-940. 
 64.  Shi,Y. and Massague,J. (2003). Mechanisms of TGF-beta signaling from cell 
membrane to the nucleus. Cell 113, 685-700. 
 65.  Singletary, S. Eva and Cristofanilli, Massimo. Defining the Clinical Diagnosis of 
Inflammatory Breast Cancer. Seminars in oncology 35[1], 7-10. 1-2-2008.  
Ref Type: Abstract 
 66.  Soria,G. and Ben-Baruch,A. (2008). The inflammatory chemokines CCL2 and CCL5 in 
breast cancer. Cancer Letters 267, 271-285. 
References 
 
83 
 67.  Sorlie,T., Perou,C.M., Tibshirani,R., Aas,T., Geisler,S., Johnsen,H., Hastie,T., 
Eisen,M.B., van de Rijn,M., Jeffrey,S.S., Thorsen,T., Quist,H., Matese,J.C., 
Brown,P.O., Botstein,D., Lonning,P.E., and Borresen-Dale,A.L. (2001). Gene 
expression patterns of breast carcinomas distinguish tumor subclasses with clinical 
implications. Proceedings of the National Academy of Sciences 98, 10869-10874. 
 68.  Sorlie,T., Wang,Y., Xiao,C., Johnsen,H., Naume,B., Samaha,R., and Borresen-
Dale,A.L. (2006). Distinct molecular mechanisms underlying clinically relevant 
subtypes of breast cancer: gene expression analyses across three different 
platforms. BMC Genomics 7, 127. 
 69.  Spaeth,E.L., Dembinski,J.L., Sasser,A.K., Watson,K., Klopp,A., Hall,B., Andreeff,M., 
and Marini,F. (2009). Mesenchymal stem cell transition to tumor-associated 
fibroblasts contributes to fibrovascular network expansion and tumor progression. 
PLoS. One. 4, e4992. 
 70.  Sun,X., Cheng,G., Hao,M., Zheng,J., Zhou,X., Zhang,J., Taichman,R., Pienta,K., and 
Wang,J. (2010). CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. 
Cancer and Metastasis Reviews 29, 709-722. 
 71.  Sund,M. and Kalluri,R. (2009). Tumor stroma derived biomarkers in cancer. Cancer 
and Metastasis Reviews 28, 177-183. 
 72.  Suwiwat,S., Ricciardelli,C., Tammi,R., Tammi,M., Auvinen,P., Kosma,V.M., 
LeBaron,R.G., Raymond,W.A., Tilley,W.D., and Horsfall,D.J. (2004). Expression of 
Extracellular Matrix Components Versican, Chondroitin Sulfate, Tenascin, and 
Hyaluronan, and Their Association with Disease Outcome in Node-Negative Breast 
Cancer. Clinical Cancer Research 10, 2491-2498. 
 73.  Teicher,B.A. (2001). Malignant cells, directors of the malignant process: role of 
transforming growth factor-beta. Cancer Metastasis Rev. 20, 133-143. 
 74.  Teicher,B.A. and Fricker,S.P. (2010). CXCL12 (SDF-1)/CXCR4 Pathway in Cancer. 
Clinical Cancer Research 16, 2927-2931. 
 75.  Tsujino,T., Seshimo,I., Yamamoto,H., Ngan,C.Y., Ezumi,K., Takemasa,I., Ikeda,M., 
Sekimoto,M., Matsuura,N., and Monden,M. (2007). Stromal myofibroblasts predict 
disease recurrence for colorectal cancer. Clin. Cancer Res. 13, 2082-2090. 
 76.  Tuxhorn,J.A., Ayala,G.E., and Rowley,D.R. (2001). Reactive stroma in prostate 
cancer progression. J. Urol. 166, 2472-2483. 
 77.  Tuxhorn,J.A., Ayala,G.E., Smith,M.J., Smith,V.C., Dang,T.D., and Rowley,D.R. (2002). 
Reactive Stroma in Human Prostate Cancer. Clinical Cancer Research 8, 2912-2923. 
References 
 
84 
 78.  Visvader,J.E. (2011). Cells of origin in cancer. Nature 469, 314-322. 
 79.  Wang,D., Park,J.S., Chu,J.S., Krakowski,A., Luo,K., Chen,D.J., and Li,S. (2004). 
Proteomic profiling of bone marrow mesenchymal stem cells upon transforming 
growth factor beta1 stimulation. J. Biol. Chem. 279, 43725-43734. 
 80.  Webber,M.M., Trakul,N., Thraves,P.S., Bello-DeOcampo,D., Chu,W.W., Storto,P.D., 
Huard,T.K., Rhim,J.S., and Williams,D.E. (1999). A human prostatic stromal 
myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in 
prostatic neoplasia. Carcinogenesis 20, 1185-1192. 
 81.  Yazhou,C., Wenlv,S., Weidong,Z., and Licun,W. (2004). Clinicopathological 
significance of stromal myofibroblasts in invasive ductal carcinoma of the breast. 
Tumour. Biol. 25, 290-295. 
 82.  Zeisberg,E.M., Potenta,S., Xie,L., Zeisberg,M., and Kalluri,R. (2007). Discovery of 
Endothelial to Mesenchymal Transition as a Source for Carcinoma-Associated 
Fibroblasts. Cancer Research 67, 10123-10128. 
 83.  Zuk,P.A., Zhu,M., Mizuno,H., Huang,J., Futrell,J.W., Katz,A.J., Benhaim,P., 
Lorenz,H.P., and Hedrick,M.H. (2001). Multilineage cells from human adipose 
tissue: implications for cell-based therapies. Tissue Eng 7, 211-228. 
 
 
 
Publications 
 
85 
10. Publications and awards 
 
PUBLICATIONS 
Welte G, Alt EU, Devarajan E, Krishnappa S, Jotzu C, Song YH. Interleukin-8 derived from 
local tissue-resident stromal cells promotes tumor cell invasion. Molecular Carcinogenisis 
2012; 51(11):861-868  
Jotzu C, Alt E, Welte G, Li J, Hennessy BT, Devarajan E, Krishnappa S, Pinilla S, Droll L, Song 
YH. Adipose tissue derived stem cells differentiate into carcinoma-associated fibroblast-like 
cells under the influence of tumor derived factors. Cellular Oncology 2011; 34(1):55-67. 
Pinilla S, Alt EU, Abdul Khalek FJ, Jotzu C, Muehlberg F, Beckmann C, Song YH. Tissue 
resident stem cells produce CCL5 under the influence of cancer cells and thereby promote 
breast cancer cell invasion. Cancer Letters 2009; 284(1):80-5. 
 
AWARD 
First Place Graduate Student Award at the M.D. Anderson Cancer Center Trainee Research 
Day 2009 for the abstract “Breast Cancer Tumor-Conditioned Media Induced Differentiation 
of Tissue Resident Mesenchymal Stem Cells to Carcinoma-Associated Fibroblast-Like Cells 
 
Acknowledgments 
 
86 
11. Acknowledgements 
 
First of all, I would like to thank Prof. Dr. Eckhard Alt for allowing me to carry out this 
research work at the University of Texas, MD Anderson Cancer Center in Houston and Prof. 
Dr. Andreas Jung for his friendly and helpful support at all times at the Ludwig-Maximilians-
University in Munich. 
I am grateful to Yao-Hua Song, M.D., Ph.D. who guided and supported me throughout my 
research year at MD Anderson Cancer Center and critically reviewed the published 
manuscript. 
I would also like to acknowledge Sendurai A. Mani, Ph.D. for stimulating discussions and 
helpful comments on this study. 
Special thanks to Jane Li from Dr. Brian Hennessy´s lab for helping me to successfully 
perform the western blot experiments. 
Thanks to all my lab colleagues at MD Anderson Cancer Center for scientific discussions and 
the nice atmosphere in the lab as well as for the pleasant time that we spent together 
outside of the lab. 
I want to thank my brother, Gregor for reviewing this manuscript and all my family, 
especially my mother who encouraged and supported me at all times. 
 
Eidesstattliche Versicherung 
 
 
87 
 
12. Eidesstattliche Versicherung 
 
 
Hiermit bestätige ich, Constantin Jotzu, dass ich die vorliegende Dissertation mit dem 
Thema «Differentiation of mesenchymal stem cells from the adipose tissue into carcinoma-
associated myofibroblasts in interaction with human breast cancer cells » selbständig 
verfasst, mich außer der angegebenen keiner weiteren Hilfsmittel bedient und alle 
Erkenntnisse, die aus dem Schrifttum ganz oder annährend übernommen sind, als solche 
kenntlich gemacht habe und nach ihrer Herkunft unter Bezeichung der Fundstelle einzeln 
nachgewiesen habe. 
Ich erkläre des Weiteren, dass die hier vorgelegte Dissertation nicht in gleicher oder in 
ähnlicher Form bei einer anderen Stelle zur Erlangung eines akademischen Grades 
eingereicht wurde. 
 
__________________________   _____________________________ 
 Ort, Datum      Constantin Jotzu 
